



Published in final edited form as:

Nat Rev Dis Primers. ; 6(1): 20. doi:10.1038/s41572-020-0153-5.

Colonic diverticular disease

Antonio Tursi^{1,†}, Carmelo Scarpignato^{2,3}, Lisa L. Strate⁴, Angel Lanas⁵, Wolfgang Kruis⁶, Adi Lahat⁷, Silvio Danese⁸

¹Territorial Gastroenterology Service, Azienda Sanitaria Locale Barletta-Andria-Trani, Andria, Italy

²Faculty of Health Sciences, LUdeS Lugano Campus, Switzerland ³United Campus of Malta, Birkirkara, Msida, Malta ⁴Division of Gastroenterology, Department of Medicine, Harborview Medical Center, University of Washington Medical School, Seattle, Washington, USA ⁵Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, Zaragoza, Spain ⁶Evangelisches Krankenhaus Kalk, Cologne, Germany ⁷Department of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel ⁸IBD Unit, Humanitas Clinical Research Hospital, Rozzano, Milan, Italy

Abstract

Colonic diverticula are outpouchings of the intestinal wall and are common anatomical alterations detected in the human colon. Diverticulosis (the presence of diverticula in the colon) remains asymptomatic in most individuals but ~25% of individuals will develop symptomatic diverticulosis, termed diverticular disease. Diverticular disease can range in severity from symptomatic uncomplicated diverticular disease (SUDD) to symptomatic disease with complications such as acute diverticulitis or diverticular haemorrhage. Since the early 2000s, a greater understanding of the pathophysiology of diverticulosis and diverticular disease, which encompasses genetic alterations, chronic, low-grade inflammation and gut dysbiosis, has led to improvements in diagnosis and management. Diagnosis of diverticular disease relies on imaging approaches, such as ultrasonography, CT and MRI, as biomarkers alone are insufficient to establish a diagnosis despite their role in determining disease severity and progression as well as in differential diagnosis. Treatments for diverticular disease include dietary fibre, pharmacological treatments such as antibiotics (rifaximin), anti-inflammatory drugs (mesalazine) and probiotics, alone or in combination, and eventually surgery. Despite being effective in treating primary disease, their effectiveness in primary and secondary prevention of complications is still uncertain.

[†] antotursi@tiscali.it.

Author contributions

Introduction (A.T. and S.D.); Epidemiology (A. Lanas); Mechanisms/pathophysiology (L.L.S.); Diagnosis, screening and prevention (W.K.); Management (C.S.); Quality of life (A. Lahat); Outlook (A.T., C.S. & S.D.); Overview of Primer (A.T.). A.T. and C.S. contributed equally and are co-first authors.

Competing interests

C.S. and A. Lanas are members of the Speakers' Bureau and of the Scientific Advisory Board of Alfasigma SpA. W.K. served as speaker, consultant and/or advisory board member for Abbvie, Ardeypharm, Falk, Ferring, Genetic Analysis, Gräfe & Unze, Institut Allergosan, Nikkiso, Otsuka and Tillots. S.D. served as speaker, consultant, and/or advisory board member for Abbvie, Allergan, Alfa Wassermann, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead, Hospira, Johnson and Johnson, Merck, MSD, Mundipharma, Pfizer Inc, Sandoz, Takeda, Tigenix, UCB Pharma, Vifor. . The remaining authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Toc Blurp

Colonic diverticular disease, characterized by sac-like protrusions on the wall of the large intestine, is one of the most common conditions detected on colonoscopy in the adult population. This Primer by Tursi and colleagues reviews the epidemiology, pathogenesis, diagnosis as well as the management of this disease.

Introduction

Diverticula, that is, sac-like protrusions in the wall of large bowel are the most frequent anatomical alteration in the human colon. Colonic diverticulosis (hereafter referred to as diverticulosis) refers to the presence of diverticula in the colon. For many years, the western lifestyle has been considered a key factor for the development of diverticulosis, owing to its comparatively high prevalence in developed countries. Indeed, the global prevalence of diverticulosis is increasing in both developed and developing countries, presumably as a result of changes in diet and lifestyle¹. The pathogenesis of diverticulosis is not completely understood but several changes are known to occur in the architecture of the colon wall, including loss of elasticity function and deposition of immature collagen fibres in the extracellular matrix, which are implicated in the formation of diverticula². The colonic wall consists of mucosa, submucosa, muscular and serosal layers. In western populations, the outpouchings involve eversion of the mucosal and submucosal layers but not the muscular layer of the colon wall (Figure 1) and, therefore, are termed false diverticula or pseudodiverticula³. In eastern populations, the eversion can involve all layers of the colon wall and these diverticula are, therefore, referred to as ‘true’ diverticula. Diverticulosis involving both false and true diverticula are generally asymptomatic, but might result in diverticulitis (inflammation of the diverticula), and colonic bleeding, which is more commonly observed in eastern populations³.

Colonic diverticular disease (hereafter referred to as diverticular disease) develops when diverticulosis becomes symptomatic, which typically involves bloating, abdominal pain and changes in bowel habit and is estimated to occur in ~25% of individuals with diverticulosis³. Diverticular disease can range in severity from symptomatic uncomplicated diverticular disease (SUDD) to symptomatic complicated disease such as acute diverticulitis or diverticular haemorrhage. SUDD is a distinct entity in which symptoms, particularly abdominal pain, can be attributed to diverticula in the presence of low-grade inflammation detected on histology but with no macroscopic signs of inflammation (Figure 1). Acute diverticulitis can range in severity from peridiverticular inflammation limited to the colonic wall (acute uncomplicated diverticulitis) to peritonitis (inflammation of the lining of abdominal cavity; complicated diverticulitis) resulting from perforations of diverticula. Diverticular haemorrhage occurs as a consequence of rupture of diverticula-associated arteries, leading to colonic bleeding). The pathogenesis of diverticular disease is less well understood than that of diverticulosis but is thought to involve genetic predisposition, gut microbiota imbalance, neuromuscular abnormalities, chronic low-grade inflammation or acute inflammation, as well as altered colonic motility² (Figure 1).

Diverticulosis is usually detected incidentally in patients undergoing endoscopy or radiological examinations. Diagnosis of diverticular disease requires combined assessment of clinical signs and biomarkers. Diagnosis of acute diverticulitis relies on cross-sectional imaging such as ultrasonography, CT and MRI, since biomarkers are often not sufficient to establish a diagnosis. Colonoscopy is generally not recommended in individuals with acute diverticulitis owing to risk of bowel perforation but is currently advised 6–8 weeks after an episode of acute diverticulitis to rule out colorectal cancer. Consensus is lacking regarding the optimal treatment options for diverticular disease, although treatment usually includes dietary fibre supplementation, pharmacological therapies (such as antibiotics and anti-inflammatory drugs) and probiotics, alone or in combination³.

In general, acute diverticulitis occurs less frequently than previously thought² and the long-standing recommendation to treat acute diverticulitis with antibiotics has been disputed of late⁴. Although diverticula can occur throughout the gastrointestinal tract (including the esophagus⁵, the stomach⁶ and the small bowel⁷), those arising in the colon are the most frequent ones.

In this Primer, we review the current knowledge of the epidemiology, pathogenesis, diagnosis, prevention and management of colonic diverticulosis and colonic diverticular disease. In addition, current and evolving tools for predicting disease outcome are discussed.

Epidemiology

The ‘true’ prevalence and incidence of diverticulosis and diverticular disease is unknown. Indeed, epidemiological data come from papers or registries, which often do not report the specific phenotype of the disease and include any condition of the whole spectrum of diverticular disease unless specified otherwise.

Prevalence and incidence

Diverticulosis—Colonic diverticula can manifest in various clinical presentations⁸. As diverticulosis is usually asymptomatic and detected incidentally, accurate estimates of its true incidence and prevalence are lacking. Nevertheless, the incidence of diverticulosis seems to be increasing globally, especially in developed countries, where approximately two-thirds of adult populations (>18 years of age) eventually develop diverticulosis¹. Age and geographic location, which is associated with different lifestyles (that is, diet and physical activity), are the two most important determinants of diverticulosis prevalence.

The prevalence of diverticulosis is very low in individuals <40 years of age and high among those >65 years of age, although, it is currently increasing, particularly among younger individuals (<40 years of age)¹. For example, in the USA, diverticulosis is the most frequent finding in colonoscopy procedures⁹ and the eighth most frequent outpatient gastrointestinal diagnosis in 2010 (Ref¹⁰). In 2009, in the USA, the reported prevalence of diverticulosis was 32.6% in individuals 50–59 years of age and 71.4% in those >80 years of age⁹. In Mexico, the prevalence of diverticulosis is in the range 1.9–9.2%, whereas in Africa the prevalence ranges from 2% in Egypt to 9.4% in Nigeria¹. Among Asian countries, the prevalence is

12.5% in South Korea and 70.1% in Japan; in Europe, the lowest prevalence was reported in Romania (2.5%) and highest prevalence was reported in Italy (51.4%)¹.

In western countries, diverticulosis was detected in the sigmoid or left colon in 90% of cases, whereas, in Japan¹¹ and South Korea¹², diverticulosis was found more frequently in the ascending or right colon (75–85% of cases). Additionally, black individuals have a higher proportion of diverticula (both in distribution and the total number) in the right colon than white individuals^{13,14}. The prevalence of diverticulosis detected on colonoscopy has also increased in Asia, from 13% in the period 1990–2000 to 24% in the period 2001–2010 (Ref¹⁵). Furthermore, frequency of right-sided diverticulosis is also increasing in western countries¹⁶.

Diverticular disease—Approximately 25% of individuals with diverticulosis develop SUDD, and an even smaller proportion develop acute diverticulitis¹. Progression to diverticulitis occurred in only ~1% of individuals with diverticulosis over 11 years of observation¹⁷. One-fifth of patients with incident diverticulitis (first occurrence of an inflamed diverticulum) will have at least one recurrent episode¹⁰. Approximately 12% of patients presenting with diverticulitis will have a complication, including perforation, abscess (accumulation of pus within the diverticulum) or fistula (a tunnel or an abnormal connection between two body parts). Diverticular haemorrhage is the most common cause of lower gastrointestinal bleeding¹⁸, with ~200,000 admissions in the USA annually. Fewer than 5% of patients with diverticulosis experience diverticular haemorrhage¹⁸.

A study involving veterans in Los Angeles, CA, reported that only 4.3% of patients (a rate of 6 cases per 1,000 patient-years) with diverticulosis developed acute diverticulitis. The median time to develop an acute episode of diverticulitis was 7.1 years and risk of diverticulitis increased with lower age at the time of diverticulosis diagnosis¹⁵. The highest reported prevalence of diverticular disease is reported in Japan (13–28 cases per million individuals), the USA (12–22 cases per million individuals) and western Europe (8–12 cases per million individuals)¹. Conversely, the prevalence of diverticular disease is low (0.1–5 cases per million individuals) in Africa and in Asia (with the exception of Japan)¹. In Europe, prevalence varies across countries, but do not follow any geographical pattern. For example, Italy, Austria and Sweden reported low prevalence, whereas Germany, France and the UK reported a higher prevalence than other European countries¹⁹. However, these differences might, at least in part, be owing to disparities in the methodology used to collect epidemiological data.

Hospitalization rates for diverticular disease have also increased in most countries. For example, in the USA, >216,000 hospital admissions were reported for acute diverticulitis without haemorrhage in 2012, a 21% increase from 2003 (Ref¹⁰). In the UK, the hospital admission rate for diverticular disease increased from 0.56 per 1,000 person-years in 1996 to 1.20 per 1,000 person-years in 2006²⁰. In Italy, in the period 2008–2015, the hospitalization rate for acute diverticulitis has been constantly increasing, with an annual change of ~1.9%²¹. Patients were mainly younger individuals (<40 years of age), particularly men. A significant increase was also noted in in-hospital mortality, especially among women (>18 years of age), the elderly (>70 years of age) and during the first hospitalization²¹. All the

above findings call for the need of increased awareness and clinical skills in the management of this common condition.

Risk factors

Diverticulosis—Differences in the prevalence of diverticulosis between countries might be owing to the low-fibre diet consumed in western countries, which has been pathogenetically linked to increased colonic intraluminal pressure that results in the formation of a diverticulum². However, findings from one study question the role of fibre in these individuals²². A Japanese study reported age, male sex, tobacco use, weight gain in adulthood, pre-diabetic conditions, alcohol consumption and increased serum triglyceride levels as risks factors for diverticulosis¹¹. Most of these factors in addition to low-fibre diet are also risk factors for diverticulosis in other areas of the world²².

Diverticular disease—Numerous risk factors for diverticular disease have been identified including non-modifiable factors such as age, sex and genetics²³ and modifiable risk factors such as lifestyle (diet and physical activity) and the use of prescription drugs^{22,24} (Table 1). In one study, people from non-western countries who migrated to Sweden had a decreased risk of hospitalization for diverticular disease compared with individuals born in Sweden, but, after a short period of acculturation to the western lifestyle, the risk increased in the immigrant population, becoming similar to the native Swedish population²⁵. On the basis of these data, ethnicity seems to be less important than lifestyle as a risk factor for diverticular disease.

The risk of hospitalization for diverticular disease, especially acute diverticulitis, is associated with modifiable risk factors. In western countries, factors that increase risk of hospitalization include obesity, high intake of red meat, hypertension, hyperlipidaemia, use of oral contraceptives, hormone replacement therapy, smoking and the use of some medications (such as aspirin, NSAIDs and corticosteroids). Similarly, factors that decrease risk of hospitalization include vigorous and regular physical activity, high educational attainment, high intake of fibre and a vegetarian diet^{26,27}. One study reported that adherence to a low-risk lifestyle, defined as low intake of red meat, high intake of fibre, vigorous and regular physical activity, a BMI of 18.5–24.9 kg/m² and no tobacco use, was associated with a reduced incidence of acute diverticulitis²⁸.

Mechanisms/pathophysiology

A number of hypotheses have been postulated to explain the pathogenesis of diverticulosis and the various manifestations of diverticular disease. Although evidence in support of some of these hypotheses is accumulating, the biological mechanisms that underlie the development of these conditions have not been fully elucidated. As mentioned earlier, the aetiology of diverticular disease is likely to be multifactorial and the mechanisms are likely to differ for different disease manifestations (Figure 2). For example, connective tissue abnormalities such as altered elastin (a key extracellular matrix protein that provides resilience and elasticity to tissue and organs) cross-linking, might predispose individuals to the development of asymptomatic diverticulosis²⁹, whereas additional changes or precipitating factors such as gut microbial dysbiosis or medication use, might be necessary

for the development of symptoms or complications such as acute diverticulitis and diverticular haemorrhage. Burgeoning evidence from genome-wide association studies (GWAS) promises to guide future research and improve our understanding of underlying biological mechanisms.

Faecal stasis and faecal impaction

A long-standing hypothesis of the development of diverticulitis suggests that faecal stasis and faecal impaction (trapping of faeces in a diverticular sac) can result in formation of a faecalith (a hard-stony mass of faeces), which might obstruct a diverticulum. This obstruction can lead to bacterial stasis and local trauma, followed by ischaemia, microperforation, inflammation and infection. In support of this hypothesis, resection specimens from patients with acute diverticulitis often contain a faecalith³⁰. In addition, diverticulitis shares many clinical and histopathological features with acute appendicitis, including obstruction of the appendix by a faecalith (an appendicolith). However, despite faecal impaction causing gut dysbiosis, no evidence directly links faecalith obstruction of diverticula to diverticulitis.

Chronic inflammation

In addition to the overt acute inflammation that occurs in acute diverticulitis, chronic, low-grade inflammation in individuals with diverticulosis might predispose them to the development of diverticulitis and SUDD. Many of the risk factors for diverticulitis such as a low-fibre diet²⁶, high red meat consumption³¹, obesity^{32,33}, smoking³⁴ and physical inactivity³⁵, which are also risk factors for cardiovascular disease³⁶ and diabetes mellitus³⁷, are known to be associated with chronic, low-grade inflammation. Thus, chronic inflammation might be the underlying mechanistic link between diet and lifestyle factors and diverticulitis. In a large, prospective study that only included men (40–75 years of age), the inflammatory potential of diet was correlated with the risk of diverticulitis after adjusting for other known risk factors, including dietary fibre intake and red meat consumption³⁸. The inflammatory potential of diet was assessed using the validated empirical dietary inflammatory pattern (EDIP) score, which is a weighted index of 9 pro-inflammatory and 9 anti-inflammatory food groups, predictive of the levels of three markers of inflammation, CRP, IL-6 and TNFRSF1B. In addition, in a nested case–control study within the same cohort, plasma levels of CRP and IL-6 were associated with risk of diverticulitis, further supporting the link between chronic systemic inflammation and diverticulitis³⁸.

Furthermore, in a small study, patients with SUDD showed increased expression of the neuropeptide receptor NK1 (also known as tachykinin 1, which is known to be involved in smooth muscle contraction and inflammation) and the proinflammatory cytokine TNF compared with individuals with asymptomatic diverticulosis, indicating that symptoms in SUDD might be mediated by chronic, low-grade inflammation and upregulation of tachykinins³⁹. In another study, patients with SUDD demonstrated elevated levels of faecal calprotectin (which mirrors neutrophil infiltration in the intestinal mucosa), whereas individuals with asymptomatic diverticulosis did not⁴⁰. However, two large, community-based studies evaluating patients undergoing routine colonoscopy found no evidence of mucosal inflammation, either based on immune markers such as IL-6, IL-10 and TNF, serum

CRP or histopathology, in patients with diverticulosis, regardless of symptoms^{41,42}. Differences in the patient population in these population-based studies can account for discrepancies in findings. For example, detection of inflammation in small case-control studies might be the result of prior episodes of diverticulitis that were not explicitly excluded. In fact, persistent endoscopic and/or histological inflammation after resolution of acute diverticulitis has been associated with increased risk of recurrent diverticulitis^{43,44}.

Alterations in the intestinal microbiota

Some risk factors for diverticulitis including low-fibre diet, obesity and physical inactivity, are known to influence the composition and function of the intestinal microbiota^{45–47}. For example, dietary fibre intake increases intestinal microbial diversity via bacterial production of short chain fatty acids (SCFAs)^{48–50}, which enhance mucosal barrier and immune function⁵¹. Indeed, the SCFA butyrate, when delivered to the colon via a microencapsulated formulation, might decrease the risk of recurrent diverticulitis⁵².

Preliminary studies indicate that the intestinal microbiota in patients with a history of acute diverticulitis differs from that of individuals with diverticulosis and those with various other intestinal conditions. Two cross-sectional studies found decreased levels of bacteria associated with SCFA production such as *Clostridiales* species and increased levels of bacteria with pro-inflammatory effects, including *Marvinbryantia* species and *Subdoligranulum* species^{53,54}, in patients with acute diverticulitis compared with controls. Carbohydrate metabolism and biosynthesis of secondary metabolites was predicted to be reduced based on a survey of marker genes in the intestinal microbial communities in patients with a history of acute diverticulitis compared with individuals with diverticulosis⁵³. Another study found that the diversity of Proteobacteria was higher in patients with acute diverticulitis than in individuals with diverticulosis. Few studies have focused on the intestinal microbiota in patients with SUDD. A study involving 8 patients with SUDD found lower levels of the SCFA-producing bacterial species *Clostridium* cluster IX, *Fusobacterium* species and Lactobacillaceae than in individuals with diverticulosis. Moreover, biopsy samples from the area of diverticulosis (that is, within 1 cm of a diverticulum in patients with SUDD had lower levels of *Akkermansia muciniphila* (a mucin-degrading bacterium that promotes epithelial barrier integrity by suppressing inflammation) than in biopsy samples obtained from a distant (at least 20 cm from a diverticulum) colonic site⁵⁵. Another study involving 28 patients with SUDD found a higher abundance of *Pseudobutyrvibrio* species, *Bifidobacterium* species and Christensenellaceae in patients with a history of acute diverticulitis than in those without a history of acute diverticulitis⁵⁶. Alterations in the faecal and urinary metabolome have also been observed in patients with SUDD^{55,57}. However, one study, comparing 226 individuals with incidental diverticulosis (asymptomatic) and 309 individuals without diverticulosis on screening colonoscopy, found that the mucosal-adherent bacterial community did not differ between these two groups⁵⁸.

Neuromuscular alterations

Diverticulosis—The development of diverticulosis has historically been attributed to a combination of increased intracolonic pressure and weakness in the colon wall. Higher intracolonic pressure has been attributed to low intake of fibre, whereas weakness in the

colon wall might be associated with ageing⁵⁹. GWAS have identified diverticulosis risk loci that contained genes involved in connective tissue integrity and intestinal motility, highlighting the importance of neuromuscular abnormalities in the development of diverticulosis⁶⁰. However, increase in the incidence of diverticulosis with age suggests that, in most cases, these neuromuscular alterations might be linked to ageing rather than genetic factors.

Individuals with diverticulosis have altered colonic connective tissue composition and collagen metabolism. Morphologically, the longitudinal and circular muscle layers become hypertrophic, which appears on colonoscopy as thickened colonic folds and a reduced lumen caliber, termed myochosis coli³⁰. Levels of tissue-degrading matrix metalloproteinases are higher in areas of the colon with diverticulosis than in those without⁶¹. Alterations in the enteric nervous system³⁰ such as reduced number of glial cells, nerve cells⁶² and intestinal pacemaker cells⁶³ as well as changes in the levels of neurotransmitters, neurotransmitter receptors and neurotrophic factors^{64,65} are also observed in individuals with diverticulosis. Colonic motility studies using 24-hour manometry (which measures the pressure and pressure waves in colon), indicate that patients with diverticulosis have increased intraluminal pressure, increased colonic response to eating and increased number of high-amplitude contractions in segments involved with diverticulosis compared with individuals without diverticulosis⁶⁶. These findings suggest that motor abnormalities either contribute to the development of diverticulosis or are the result of diverticulosis.

Diverticular disease—Neuromuscular disturbances are also associated with symptoms in patients with diverticular disease. Patients with SUDD, but not individuals with diverticulosis, have heightened perception of distention in colonic segments involved with diverticulosis and in the rectum⁶⁷. This visceral hypersensitivity might be mediated by chronic, low-grade inflammation and upregulation of tachykinins³⁹. Furthermore, in patients with SUDD but not in individuals with diverticulosis, nerve fibre sprouting was found to be increased in the region of diverticulosis, which might be the cause of visceral hypersensitivity and, therefore, be involved in symptom generation⁶⁸. Additionally, the type I to type III collagen ratio, cross-linking of collagen fibers⁶⁹ and levels of tissue-degrading matrix metalloproteinases⁶¹ are increased in patients with diverticular disease. It is not clear whether these changes are related to the development of diverticulosis itself or to symptoms and complications of diverticular disease.

Genetics

Several lines of indirect evidence suggest a genetic basis for diverticulosis and diverticular disease. First, as discussed earlier, the higher prevalence of diverticulosis and the left vs right colon distribution in western countries vs eastern countries might have an underlying genetic basis²⁵. Second, diverticular disease is common in several genetic syndromes that are caused by mutations in genes that are also implicated in the development of diverticular disease. For example, early-onset, extensive diverticulosis occurs in patients with inherited connective tissue disorders such as Marfan syndrome, Ehlers–Danlos syndrome, Coffin–Lowry syndrome and Williams–Beuren syndrome^{70–72}. Third, two large population-based familial aggregation studies in Scandinavia found that the risk of hospitalization for diverticular

disease was higher in the siblings of individuals with diverticular disease than in general population and higher in monozygotic twins than in dizygotic twins; these studies estimated that ~50% of the risk for diverticular disease requiring hospitalization was inherited^{73,74}.

Case-control studies have identified genetic variants within candidate genes implicated in diverticulosis and diverticulitis. A study of 433 individuals with diverticulosis and 285 individuals without diverticulosis identified an association between rs3134646 (a variant of *COL3A1*, encoding type III collagen) and diverticulosis in white men⁷⁵. Two smaller case-control studies identified an association between rs7848647, a variant within *TNFSF15* (encoding a cytokine of the TNF family) and diverticulitis requiring surgery⁷⁶. Another study found that a variant in *RPRM* (encoding reprimin, a protein involved in cell cycle regulation and DNA repair), was linked to the presence of diverticulosis⁷⁷. Finally, a rare SNP in *LAMB4* (encoding laminin subunit $\beta 4$, a constituent of the extracellular matrix) was identified in five family members with young-onset (<52 years of age) diverticulitis⁷⁸.

Three GWAS have identified susceptibility loci for diverticular disease⁷⁹. In a study from Iceland, variants in *ARHGAP15* (encoding proteins that regulate GTPase activity) and *COLQ* (encoding the collagen-tail subunit of acetylcholinesterase in the neuromuscular junction) were associated with diverticular disease in hospitalized patients and variants in *FAM155A* (encoding a protein of unknown function) were associated specifically with complicated diverticulitis or diverticulitis requiring surgery⁸⁰. A larger GWAS involving >27,000 individuals with diverticular disease and 382,000 individuals without diverticulitis, diverticular haemorrhage or known diverticulosis from the UK Biobank identified 40 loci with significant associations with diverticular disease and 112 loci with suggestive associations⁶⁰. In a separate American cohort of 2,572 individuals with diverticular disease and 28,649 healthy individuals without these diagnoses, eight significant and two suggestive loci were replicated⁶⁰. The identified risk loci contain genes involved in the immune system, intestinal motility, cytoskeleton organization, cellular adhesion, the extracellular matrix and membrane transport. The association with *COLQ* variant was confirmed in the UK study and the associations with *ARHGAP15* and *FAM155A* variants were confirmed in both the UK and the American cohorts, but not the association with *TNFSF15* (Ref⁶⁰). The UK Biobank was again used in a slightly larger GWAS with replication in a European sample involving 3,893 individuals with diverticular disease or diverticulosis and 2,829 healthy controls⁸¹; 48 loci with significant associations were identified, of which 12 were novel and 35 were replicated. For most loci, the associations were similar for diverticulosis and diverticulitis, and no overlap was identified between genome-wide significant variants for diverticular disease and those previously identified for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). However, mutations in 12 of the lead candidate genes associated with diverticular disease are involved in 18 monogenic syndromes⁷⁹. The functions of the identified candidate genes further supported a role for impaired neuromuscular, mesenteric smooth muscle and connective tissue function in the pathogenesis of diverticular disease⁷⁹. In addition, one of the identified candidate genes, *PHGR1*, which is involved in gastrointestinal epithelial cell function, was specifically associated with diverticulitis⁸¹.

Diagnosis, screening and prevention

Diagnosis

The aims of diagnostic process are not only to merely diagnose diverticular disease, but to identify the different phenotypes, namely diverticulosis, SUDD and diverticulitis. In diverticulitis, it is important to recognize the severity and complications (that is, uncomplicated disease from complicated disease, which has abscess, fistula and stricture). Exact diagnosis is the prerequisite for appropriate treatment strategies. While recognizing chronically recurrent or complicated episodes of diverticulitis is straightforward, diagnosis of chronic SUDD can be challenging. Unspecific symptoms like bloating, pain and altered bowel movements, without macroscopic pathology in colonoscopy and/or imaging might make the differential diagnosis with IBS difficult. Here, biomarkers (for example, faecal calprotectin) might be of help.

If diverticular disease (including acute diverticulitis) is suspected, the first step is to obtain a detailed medical history and perform a physical examination, to assess factors that affect disease outcomes and treatment such as comorbidities and medications and to assess indicators of disease severity such as fever and peritonitis⁸².

Clinical evaluation including laboratory tests alone, is not accurate enough to establish a diagnosis of diverticular disease. A large study conducted in the Netherlands has indeed demonstrated that clinical evaluation has limited sensitivity (68%; a positive predictive value of 65%)⁸³. Furthermore, clinical evaluation alone resulted in an incorrect diagnosis in 34–68% of cases^{84,85}, which might delay appropriate treatment, cause redundant investigations and result in unjustified hospitalization. Moreover, biomarkers are not specific enough for an initial diagnosis (see below).

Cross-sectional imaging—Traditionally, imaging of diverticula and related disease was performed by barium enema. While the detection rate of colonic diverticula is high and more accurate than that obtained by colonoscopy⁸⁶, barium enema is not an appropriate imaging technique to diagnose acute diverticulitis. Indeed, one systematic review found low sensitivity and specificity of barium enema in comparison to modern cross-sectional imaging⁸⁷. However, in selected cases (for example, in patients with intestinal stenosis), barium enema can be still indicated.

In contrast to barium enema and colonoscopy, cross-sectional imaging modalities such as ultrasonography, CT and MRI can display the whole colonic wall, thereby enabling the visualization of peridiverticular tissue and alterations in the bowel wall⁸⁸. Thus, these methods are the mainstay for the diagnosis of diverticular disease and mandatory for the accurate diagnosis of diverticulitis⁸² (Figure 3).

Although CT is currently the widely-adopted diagnostic approach, technological advances have led to an increasing use of ultrasonography worldwide^{89–91}. An early comparison of ultrasonography and CT found very similar diagnostic accuracy for these two approaches⁸⁴. In fact, a systematic review with meta-analysis confirmed that ultrasonography and CT did not differ substantially in sensitivity (92% and 94%, respectively) and specificity (90% and

99%, respectively)^{92,93}. Of note, pathologic conditions other than diverticular disease were more often described with CT⁹². A drawback of this meta-analysis is that the studies included patients across the whole spectrum of diverticular disease. A study comparing the diagnostic accuracy of ultrasonography and CT in SUDD, acute uncomplicated and complicated diverticulitis found a clear superiority of CT in diagnosing complicated diverticular disease whereas the two approaches had comparable diagnostic accuracy in SUDD⁹⁴. Data regarding the diagnostic accuracy of MRI in diverticular disease are sparse but promising. Most interestingly, the only comparative study between CT and MRI in patients admitted to the emergency room with clinically suspected acute diverticulitis reported a sensitivity of 94% and a specificity of 88% for MRI. Interestingly, the diagnostic accuracy of MRI was found to be better in younger (<60 years of age) than in older patients⁹⁵.

Typical ultrasonography findings in diverticular disease include hypoechoic thickening of the bowel wall, diverticula with surrounding inflammation that appears as a hyperechoic rim, fluid collection, abscesses or fistulas^{92,93,96,97}. In addition to these features, CT can also detect distant abscesses (for example, in the pelvis), fat stranding (to detect mesenteric inflammation) and contrast extravasation (to detect perforation). However, the diagnostic yield of ultrasonography and CT might differ in some aspects, the two being complementary rather than competing techniques. For example, ultrasonography is a dynamic investigational tool that provides information on the motor activity of the bowel. As a matter of fact, the pressure of the ultrasonography probe can cause pain, which can lead the operator to focus on the given abdominal area. By contrast, CT has a superior penetration depth and can better display the retroperitoneal and pelvic space, regardless of the presence of intestinal gas or obesity. After an episode of acute diverticulitis, findings from CT, in contrast to ultrasonography, have substantial prognostic value⁹⁸. Indeed, colonic wall thickness and severity of diverticulitis detected by CT were predictive of the need for elective partial colectomy⁹⁹. In contrast to ultrasonography and MRI, CT involves exposure to radiation, which limits its repeated use. Acute diverticulitis might progress rapidly (in <12 hours). By nature, inflammation is a dynamic process and an appropriate visualization would require reiterative examinations. For example, the size of a visible abscess can be closely followed, which may lead to escalating procedures such as drainage or even surgery. Ultrasonography can be replicated as often as it is useful for difficult decision making.

In principle, for all imaging methodologies (especially ultrasonography), diagnostic accuracy is operator-dependent and is better performed in referral centres (where all diagnostic procedures are usually available) than in a general hospital setting^{89,100}. The choice of diagnostic procedure is usually determined by local availability and skill. Ideally, ultrasonography might be used as a first step, followed by CT if needed⁸⁹.

Colonoscopy—Traditionally, colonoscopy is avoided in patients with acute diverticulitis because of perceived hazards from the procedure¹⁰¹, especially an increased risk of local or distant perforation, although this risk was not confirmed in one small study¹⁰². As the main pathophysiological features of acute diverticulitis take place *outside* the colonic wall, colonoscopy has only a minor role in the initial diagnosis of acute diverticulitis. In a prospective study, all patients with confirmed acute diverticulitis had initial colonoscopies.

Patients improving rapidly within some days demonstrated no pathologies on colonoscopy, whereas four out of 23 patients with persistent diverticulitis (>1 week) benefited from early colonoscopy¹⁰², which helped to identify the reason for persistent diverticulitis or to change the final diagnosis in these patients. Differential diagnoses for diverticular disease include IBD, IBS, appendicitis, microscopic colitis, cancer or segmental colitis associated with diverticula (SCAD). SCAD will not be discussed in this review because it is now considered as a forerunner of IBD rather a complication of diverticular disease³. Colonoscopy is however advisable prior to elective surgery in patients with acute diverticulitis to rule out other colonic findings, including neoplastic lesions⁸².

Diverticular haemorrhage typically presents as painless, intermittent and large volume of lower gastrointestinal bleeding¹⁰³, which often stops spontaneously but can also be life threatening^{103–105}. Diagnostic and interventional modalities available to diagnose and treat diverticular haemorrhage include colonoscopy, angiography, radionuclide scintigraphy (tagged red blood cell scanning) and CT. Colonoscopy can precisely identify the origin of bleeding and offers a range of effective interventions for haemostasis. In prospective studies and in a nationwide database study, colonoscopy within 24 hours of acute lower gastrointestinal bleeding was related to shorter hospital stay and lower hospitalization costs^{106,107}. High volume upper gastrointestinal bleeding leads to acute-onset haematochezia (fresh blood in stool), which needs differential diagnosis before investigation of the colon. At this time, it is recommended either to insert a gastric tube or to perform upper gastrointestinal endoscopy prior to colonoscopy¹⁰⁸. Furthermore, several guidelines recommend colonoscopy within 24 hours after bowel cleansing in patients with severe haematochezia¹⁰⁷.

Where there is an identifiable source of bleeding, endoscopic haemostasis must be attempted. If endoscopic treatment is not possible, angiography with embolization can be performed following identification of the bleeding. In all other cases of persistent bleeding or in the event of a clinically relevant bleeding relapse after initial endoscopic or angiographic haemostasis, surgical therapy must be undertaken urgently^{18,82,104,108}. If surgery is inevitable, precise knowledge of the localization is crucial for any surgical process that is required. Colonic resections in patients with diverticular haemorrhage with unclear localization of bleeding showed a postoperative mortality of 43% in comparison to 7% in patients with well-defined localization of bleeding¹⁰⁹.

The need for routine colonoscopy in asymptomatic patients after a flare of acute diverticulitis is intensely debated owing to the long-standing discussion on the association of diverticular disease with simultaneous colonic neoplastic lesions. A large meta-analysis involving 50,445 patients with acute diverticulitis analysed 31 studies conducted worldwide and reported substantial heterogeneity between the study results ($I^2=57%$, $P<0.01$)¹¹⁰. The meta-analysis reported a pooled prevalence of 1.9% of associated colorectal cancer (CRC). Notably, the risk for CRC was sixfold higher in patients with complicated diverticulitis than in patients with uncomplicated diverticulitis. Additionally, the meta-analysis reported that colonoscopy detected a pooled prevalence of 22.7% of polyps, (4.4% of the which were advanced adenomas, 14.2% were adenomas and 9.2% were hyperplastic polyps).

Since diverticular disease and CRC share some risk factors (such as age, diet and body weight), the coexistence of both diseases in the general population is expected. The clinically relevant issue is that the symptoms of diverticular disease might mask signs of CRC, which was significantly associated with longer diagnostic intervals¹¹¹. Taking all these considerations into account, colonoscopy should be considered after an episode of acute diverticulitis, provided that it has not already been performed¹¹¹. Owing to risks of perforation, a delay of 6–8 weeks after treatment is generally recommended¹¹². According to two meta-analyses^{112,113}, most studies performed colonoscopy within 6–8 weeks (and in any case within 6 months) after the index episode. However, the rate of detecting CRC via endoscopy is relatively low, especially after an episode of uncomplicated acute diverticulitis¹¹⁴; a meta-analysis of 11 studies¹¹³ reported a low risk of malignancy after a CT-proven episode of acute uncomplicated diverticulitis (0.7%, 95% CI 0.4–1.4) in comparison to patients with complicated diverticulitis (1.6%, 95% CI 1.6–2.8) at subsequent colonic evaluation. According to a meta-analysis of 17 studies, routine colonoscopy can be omitted in patients with uncomplicated diverticulitis if CT imaging is otherwise clear¹¹⁵. However, as the prevalence of precursor lesions such as adenomas is large and the procedure is relatively safe, colonoscopy should be offered to all patients (especially those >50 years of age) after an episode of acute diverticulitis.

Biomarkers—Biomarkers might substantiate clinical suspicion and can be useful for assessing disease severity and for disease monitoring¹¹⁶. For example, proinflammatory markers such as CRP, erythrocyte sedimentation rate and leukocyte count, faecal calprotectin and procalcitonin might have a role as biomarkers of diverticular disease, given the importance of inflammatory process in the disease pathophysiology.

On the ground of the available data, CRP is the most useful biomarker for diverticulitis. A comparative study found that a high index CRP value was the best predictor of severe complications in patients with acute diverticulitis¹¹⁶. Additionally, serum CRP concentrations are closely related to clinical and histological severity of diverticulitis. Low CRP levels (<50 mg/l) are indicative of acute uncomplicated diverticulitis, whereas CRP >200 mg/l can indicate complications such as perforation with peritonitis or abscesses.

Faecal calprotectin is a useful biomarker to follow-up therapy outcomes; its levels decrease in patients responding to treatment, whereas persistent high levels indicate treatment failure¹¹⁷. A systematic review examining the use of faecal calprotectin to distinguish IBS from IBD¹¹⁸ reported that faecal calprotectin levels >50mg/g detected IBD with pooled sensitivity of 93% (range 83–100%) and pooled specificity of 94% (60–100%)¹¹⁹. Faecal calprotectin testing seems to be the most sensitive preliminary test for discriminating IBD from IBS and is superior to serum CRP in its diagnostic accuracy¹²⁰, suggesting that faecal calprotectin can also be a valuable tool to discriminate IBS and SUDD⁴⁰. Typical symptoms of SUDD are pain localized in the left lower abdomen without signs of inflammation¹²¹. Though the clinical signs of IBS and SUDD might show some similarities, an in-depth history (such as the course of pain) and faecal calprotectin levels might help to clarify the diagnosis¹²². A prospective study comparing faecal calprotectin levels in patients with SUDD and IBS according to Rome III criteria described significantly higher faecal calprotectin levels in SUDD than in IBS, which decreased after successful treatment⁴⁰.

Although faecal calprotectin is a well-established biomarker of inflammatory activity in IBD, its utility for diverticulitis remains to be fully established.

According to guidelines, the diagnostic algorithm for a range of bacterial infectious diseases comprises measurement of serum procalcitonin (to identify sepsis¹²³) before commencing antibiotic therapy^{124,125}. Its use has led to a decrease in antibiotic prescription¹²⁶, a goal that is also pursued in the treatment of diverticulitis. One study demonstrated a high diagnostic accuracy of procalcitonin in differentiating uncomplicated and complicated diverticulitis¹²⁷. However, the role of procalcitonin needs to be further investigated.

To date, among many other proteins that were studied as potential biomarkers for diverticular disease, none has achieved clinical significance¹¹⁷. Also serum vitamin D levels were shown to be associated with the severity of endoscopic mucosal alterations in diverticular disease¹²⁸. However, overall, CRP remains the most useful biomarker to date.

Classification

DICA—A study found that the persistence of mucosal alterations after an episode of acute diverticulitis might have a prognostic role on the risk of diverticulitis recurrence, showing for the first time that endoscopic examination can be useful in predicting the outcome of the disease⁴⁴. The Diverticular Inflammation and Complication Assessment (DICA)¹²⁹, developed on the basis of colonoscopy, is a three-stage severity score that classifies the disease into mild, moderate or severe¹²⁹ (Figure 4). DICA takes into account several main features and sub features: the four main items are extension of diverticulosis (left or right and the length of colon involved), the number of diverticula in each colonic segment (15 or >15 diverticula), the presence of inflammation (edema and/or hyperemia, erosions, SCAD. Although now considered a precursor of IBD, it was included in the original DICA classification. The results of a prospective ongoing study will tell us whether SCAD should be excluded from the classification¹³⁰, and the presence of complications (rigidity, stenosis, pus and bleeding). When diverticula were detected during colonoscopy, they were described as ‘scattered’, ‘scanty’, ‘diffuse’ or ‘numerous’. Each feature and sub-feature have a numerical score, and the sum of the scores leads to three different DICA scores: DICA 1 (3 points), DICA 2 (4–7 points), and DICA 3 (>7 points)¹²⁹ (Figure 4). This classification might be predictive of disease outcome; for example, in a 2016 retrospective study, the DICA score was predictive of the risk of acute diverticulitis occurrence and/or recurrence and the risk of surgery¹³¹. A 3-year prospective, international validation study is currently ongoing¹³⁰ and preliminary analysis of the results at one-year follow-up confirmed the results of the retrospective study¹³². The DICA Score needs of course further validation. Provided early results (at 1-year) can be confirmed, follow-up colonoscopy after acute diverticulitis can provide additional benefits to the existing classification.

Diverticulitis—Several classification systems for diverticulitis are available, including two clinical (Hansen/Stock and Köhler classifications) and three radiological (modified Hinchey, Ambrosetti and Dharmarajan classifications)¹³³. The modified Hinchey classification is the most commonly used owing to its high sensitivity (94%) and specificity (99%) and gives a good overview often with important additional information on other pathology¹³⁴. Apart

from diagnosing diverticulitis, CT has become important in determining the severity of the disease.

The original classification developed by Hinchey et al. was a surgical classification of the perforated acute diverticulitis with four individual stages based on intraoperative findings¹³⁵ (Figure 5). This classification was very simple with a good prognostic value, but yielded limited correlation with CT findings. A modified version of this classification, which is now the most commonly used, consists of five (instead of four) different categories¹³⁶. When present, abscesses are differentiated depending on their location between confined, pericolic (Ib) and distant (intra-abdominal or intra-peritoneal) abscesses (II). The initial goal of this modification was to discriminate patients manageable with imaging-guided percutaneous drainage from those requiring surgery.

Prevention

As already discussed, diverticulosis has been hypothesized as being the result of a low-fibre diet¹³⁷. More modern scientific work including population-based studies of twins and siblings⁷⁴ as well as GWAS⁸¹ have highlighted the genetic background of the disease indicating a multifactorial aetiology, which is difficult to modify. Indeed, there are currently no evidence-based measures for primary prevention of diverticulosis. Although only a small proportion of individuals with diverticulosis develop diverticular disease, the absolute number of individuals affected by diverticular disease is sufficient to place an enormous burden on national health systems, which makes primary prevention highly desirable. Modifiable risk factors offer opportunities for primary prevention of diverticular disease in patients with known diverticulosis²³. Of note, as risk factors have typically been identified in retrospective observational studies, these weak data only allow recommendations for prevention to be made (Table 1).

Management

The therapeutic approach to diverticular disease is tailored to the severity of the disease. The presence of diverticula is not an indication for pharmacological therapy, as most individuals with diverticulosis will not progress to symptomatic disease.

SUDD

In patients with SUDD, pharmacological therapy should aim to reduce both the intensity and frequency of symptoms and to prevent complications^{138,139}. Although patients with SUDD complain of mild to moderate pain and bloating as well as bowel changes, their quality of life is markedly impaired and can be improved by medical treatment¹⁴⁰. Treatments for SUDD include fibre, antibiotics (including the poorly absorbed antibiotic, rifaximin), anti-inflammatory drugs such as mesalazine or balsalazide and probiotics, alone or in combination^{3,139}.

Fibre—A high-fibre diet has been and is still recommended for patients with diverticular disease. However, a systematic review¹⁴¹ concluded that evidence supporting alleviation of symptoms in patients with SUDD with a high-fibre diet or dietary supplements of fibre is

very low. Indeed, most studies had substantial methodological limitations (for example, the experimental design was not always suitable to answer the clinical question) and the therapeutic regimens used were heterogeneous¹⁴¹. Thus, the benefit of dietary or supplemental fibre in the treatment of SUDD needs to be established.

Poorly absorbed antibiotics—The rationale for the use of poorly absorbed antibiotics, which display a high intraluminal availability, relies on the evidence that diverticula, in predisposed individuals, might favor faecal entrapment. This will be followed by bacterial overgrowth and potential breakdown of the epithelial lining, leading to bacterial translocation, mucosal inflammation and complications¹⁴², which leads to complicated diverticular disease. Studies showing the presence of dysbiosis in patients with SUDD^{55,57} and diverticulitis¹⁴³ strongly support this hypothesis. Antimicrobial drugs are shown to reduce colonic H₂ production and gas-related symptoms¹⁴⁴. In addition, antimicrobial therapy causes a rise in mean stool weight in subjects on a constant fiber intake, most likely because of a reduced fiber degradation consequent to the decline in bacterial population¹⁴⁵. Both these findings represent an additional rationale for antibiotic use in diverticular disease. The reduction in gas production and the increase of faecal mass both reduce the intraluminal pressure, thus improving symptoms and decreasing the enlargement and stretching of diverticula as well as the generation of new diverticula¹⁴⁶.

In a double-blind, placebo-controlled, randomized clinical trial (RCT)¹⁴² as well as open studies¹⁴⁷ and their meta-analyses^{148,149}, the combination of rifaximin and (soluble or insoluble) fibre was more effective in reducing symptoms in patients with SUDD than fibre alone. As the number needed to treat (NNT) was found to be 3, the treatment should be considered cost-effective. Rifaximin is a poorly absorbed, gastrointestinal tract-targeted, antibiotic that displays both eubiotic and anti-inflammatory properties^{150,151}. It is also very effective and safe in the treatment of small intestine bacterial overgrowth (SIBO, the most widely detected form of gut dysbiosis)¹⁵², which underlies several (organic and functional) gastrointestinal disorders¹⁵³. The combination of rifaximin (given for 7–10 days, every month) and soluble fibre such as glucomannan (a plant extract capable of absorbing up to 200 times its weight in water), was very effective in treating SUDD, a finding confirmed in real-life studies from both gastroenterology and general practice^{154,155}. One trial found that rifaximin alone (800 mg/day, 10 days a month) was more effective than dietary fibre in improving symptoms and quality of life in patients with SUDD¹⁵⁶. The efficacy of this drug appears to be maintained in the long-term, as shown by a large retrospective study with a 8-year follow-up¹⁵⁷. Indeed, since the diverticula do not disappear (if anything, increase) and the SIBO can recur after months, provided predisposing conditions are not eliminated¹⁵⁸. SUDD is a chronic relapsing disease and needs a cyclic (7–10 days a month) treatment. Indeed, several national guidelines^{159–165} recommend long-term cyclic administration of rifaximin for the treatment of SUDD.

According to the European Pharmacopeia, rifaximin shows crystal polymorphism with five distinct crystal forms, namely α , β , γ , δ and ϵ ¹⁶⁶. In vitro studies demonstrated different dissolution and solubility rates of these polymorphs, and in vivo investigations in dogs found significantly different pharmacokinetic patterns amongst the various crystal forms, with the γ polymorph displaying the highest systemic bioavailability¹⁶⁶. In addition to crystal

polymorphs, an amorphous form of rifaximin also exists. All the above-mentioned clinical studies were performed with the rifaximin- α . It is worthwhile to emphasize that the therapeutic results obtained with this polymorph should not be translated sic et simpliciter to the generic formulations of rifaximin, which do not claim containing only rifaximin- α and will display significantly higher systemic absorption in both health and disease, losing the features (especially safety) of a poorly absorbed antibiotic¹⁶⁷.

The spread of antimicrobial resistance is one of the leading public health problems worldwide, which has been accelerated by the overuse and misuse of antimicrobial drugs¹⁶⁸. Antimicrobial stewardship programs are shown to improve patient outcomes, reduce antimicrobial adverse events, and decrease antimicrobial resistance¹⁶⁹. In digestive diseases, such programs have mainly been implemented in the treatment of cirrhotic patients, widely considered “frail” and susceptible to healthcare associated infections¹⁷⁰. Being poorly absorbed, rifaximin displays a very low risk of systemic resistance¹³⁷. Microbial resistance within the gastrointestinal tract is rare and transient, owing to the high local concentration of the drug and the absence of horizontal transmission. *Clostridium difficile* infection is not usual in patients receiving rifaximin in absence of predisposing conditions such as hospitalization and immunosuppression, which are uncommon in patients affected by SUDD¹⁷¹. In the TARGET 3 trial, short-term repeat treatment with rifaximin had no apparent long-term effect on stool microbial susceptibility to rifaximin, rifampicin, and non-rifamycin antibiotics¹⁷².

Anti-inflammatory drugs—Mesalazine (5-aminosalicylic acid) is an established anti-inflammatory drug with multiple pharmacological effects, although the mechanism(s) of action have not been fully elucidated¹⁷³. In diverticular disease, mesalazine might exert anti-inflammatory activity, thereby improving chronic, low-grade inflammation¹⁷³ or it can modulate nociception¹⁷³. In patients with SUDD, one double-blind study showed its efficacy in providing pain relief during symptomatic flares¹⁷⁴ whereas another study found mesalazine was effective in maintaining remission¹⁷⁵ than placebo. A systematic review¹⁷⁶ found that mesalazine provided better symptom relief than placebo, a high-fibre diet or low-dose rifaximin in patients with SUDD.

Probiotics—In contrast to antibiotic treatment, probiotics are a less invasive and more physiological approach to treat the microbial dysbiosis in patients with diverticular disease. The most widely used probiotic mixtures contain *Lactobacilli* and *Bifidobacteria*, but yeasts (such as *Saccharomyces boulardii*) are also used with good clinical results. Probiotics restore the intestinal microecology by competitively inhibiting pathogenic bacterial overgrowth at the mucosa, decrease bacterial translocation by enhancing tight junction integrity and downregulate pro-inflammatory cytokines (such as TNF). All of these actions lead to improvement of mucosal defense, a feature that is potentially beneficial in the treatment of diverticular disease¹⁷⁷.

Despite these potential benefits, the available evidence for efficacy of probiotics in treating SUDD is poor. Indeed, the designs of the 11 published studies were very heterogeneous and only 2 of these studies were double-blinded and randomized¹⁷⁸. For example, some trials investigated symptom improvement whereas others assessed the maintenance of remission

of abdominal symptoms. Furthermore, the patient populations were small and the duration of follow-up was short (never >12 months). Inclusion criteria and the probiotic formulations that were used (single strain or multi-strain) were different, making any comparison of the results from different studies difficult. Accordingly, a critical analysis of the available data suggests a beneficial effect of in treating SUDD, but does not permit any evidence-based definite conclusion^{177,178}. Indeed, the Italian Consensus Conference on Diverticular Disease¹⁶¹ and the guidelines of the Italian Society of Colon and Rectal Surgery¹⁶² stated that there is insufficient evidence to conclude the efficacy of probiotics in reducing symptoms of patients with diverticular disease. However, probiotics might be useful in combination with other therapies. In one double-blind, randomized, placebo-controlled study, combination therapy with cyclic mesalazine and a probiotic (*Lactobacillus casei DG*) seemed to be more effective than placebo or either treatment alone in maintaining remission of SUDD¹⁷⁵. Owing to the small sample size of this study, larger trials are required to confirm this interesting observation.

Primary prevention of acute diverticulitis

Progression from SUDD to diverticulitis is uncommon because the disease course is often benign. In a prospective, long-term study¹⁷⁹, 97% of patients with SUDD had mild or no symptoms after a median follow-up of 66 months and only 2.5% of patients developed acute diverticulitis. Prevention (both primary and secondary) of acute diverticulitis is challenging. Although studies on medical therapies to reduce occurrence and recurrence of diverticulitis are available, most of them are of poor quality and management is often empirical rather than evidence-based.

A vegetarian diet and high intake of dietary fibre lowered the risk of hospitalization and mortality from diverticular disease²⁶. Both rifaximin and mesalazine have been used in the attempt of preventing the occurrence of diverticulitis in patients with SUDD, but the evidence in favor of their use is low. Two meta-analyses^{148,149} found that rifaximin in combination with fibre is more effective than fibre alone in preventing acute diverticulitis, a trend that is also observed in daily clinical practice¹⁵⁷. The therapeutic value of rifaximin was however quite low (NNT = 59)¹⁴⁹. A meta-analysis¹⁸⁰ found that mesalazine also prevented diverticulitis occurrence in patients with SUDD. However, the analysis included only two RCTs and 221 patients and showed a moderate level of heterogeneity between trials, precluding definite conclusions.

Acute diverticulitis

Management of acute diverticulitis depends on the severity of the condition (such as uncomplicated or diverticulitis complicated with abscess, perforation or peritonitis) as well as on the presence of comorbidities^{22,23,181,182}. Most patients admitted with acute diverticulitis respond to conservative treatment, although 10–20% of patients will eventually require surgery.

Acute uncomplicated diverticulitis—For most patients with uncomplicated diverticulitis (that is, patients who are immunocompetent, display no comorbidity, can tolerate oral intake and have outpatient support), outpatient management is possible (Figure

6). In the setting of acute uncomplicated diverticulitis, for low-risk patients characterized by normal leukocyte count and low CRP (together with absence of fever), outpatient treatment is feasible and omission of antimicrobial therapy is safe¹⁸³. A large study that analysed >1,000 patients with CT-proven acute uncomplicated diverticulitis found that patients with a systemic comorbidity, vomiting, symptoms lasting >5 days or CRP levels >140 mg/L at initial presentation, had a higher risk of developing a 'complicated course of initially uncomplicated diverticulitis', requiring intensive treatment and eventually surgery¹⁸⁴. Two studies confirmed high CRP concentrations as the predictive factor for a worse outcome (that is, development of complicated disease)^{185,186}. These studies also found that systemic inflammatory response syndrome (which is an exaggerated defense response of the body to a noxious stressor such as infection, trauma, surgery, acute inflammation, ischemia or reperfusion, or malignancy to name a few), high pain score and pharmacologically-induced immunosuppression predict a worse outcome of uncomplicated diverticulitis.

When patient classification was accurate, the outpatient approach proved to be safe and cost-effective^{187–190}. Treatment usually consists of 7–10 days of oral broad-spectrum antimicrobial therapy, including coverage against anaerobic microorganisms. The most popular combination is ciprofloxacin plus metronidazole, but other regimens are also effective. A Cochrane review¹⁹¹ found a non-inferiority between different antibiotic regimens (cefoxitin versus gentamicin-clindamycin combination) and treatment lengths (24–48 hours intravenous antibiotic treatment versus longer treatments). In uncomplicated sigmoid diverticulitis, a study reported no difference symptom improvement between a short 4-day course and a 7-day antibiotic course¹⁹². Although not rigorously studied, a low-fibre liquid diet is commonly recommended as fibres can be entrapped into diverticula. This is however, more tradition than evidence-based. In recent years, two studies have shown that an unrestricted diet is not associated with an increase of diverticular complications^{193,194}.

Although antimicrobial therapy has long been the cornerstone of acute diverticulitis treatment, routine use of this therapy in patients with uncomplicated diverticulitis has been challenged¹⁹⁵ owing to the evolving concepts in the pathogenesis of the disease (shifting from bacterial infection to an inflammatory process), the growing concerns about antibiotic overuse and the results of several studies. Two RCTs^{196,197} questioned the antimicrobial use and showed that observational treatment can be considered appropriate in patients with uncomplicated diverticulitis. Five meta-analyses (including RCTs, cohort studies and case-control studies)^{198–202} demonstrated that clinical outcomes between patients treated with and those treated without antimicrobials are not substantially different. Indeed, no substantial differences were evident in the proportion of patients requiring additional treatment or intervention, rate of readmission or deferred admission, need for surgical or radiological intervention, and recurrence or complication rate. One meta-analysis¹⁹⁸ found that the only variable that was significantly associated with treatment failure in the non-antibiotic treatment group was associated comorbidities, an expected finding in clinical practice that will likely apply to immunocompromised patients and pregnant women. Post-hoc analysis of the DIABOLO trial²⁰³ (a multicentre RCT that compared antibiotic treatment and observational treatment in 528 patients with uncomplicated acute diverticulitis²⁰⁴) found more patients with fluid collections and a longer inflamed colonic

segment in the group of patients with a complicated course of initially uncomplicated diverticulitis.

Avoiding antimicrobial agents in the treatment of patients with uncomplicated acute diverticulitis is associated with a substantially shorter hospital stay^{205,206}. Omitting antibiotics in the treatment of acute uncomplicated diverticulitis did not result in a higher incidence of complicated diverticulitis, recurrent diverticulitis or need for surgical intervention even at long-term follow-up²⁰⁷. As a consequence, the guidelines from Italian medical¹⁶¹ and surgical¹⁶² societies and from the World Society of Emergency Surgery²⁰⁶ as well as from the American Gastroenterological Association (AGA)²⁰⁸ recommend selective use of antimicrobial drugs rather than routine administration in patients with acute uncomplicated diverticulitis.

Patients with severe presentations of uncomplicated diverticulitis (that is patients with high CRP levels, high fever, vomiting or long-lasting symptoms), those unable to tolerate oral intake or without outpatient support should be hospitalized, should receive intravenous fluids intravenous antimicrobial drugs (such as a beta-lactam antibiotic with beta-lactamase inhibitor, or metronidazole and a third-generation cephalosporin)^{22,23,181,182}.

In both low-risk and high-risk patients, symptoms usually improve within 2–3 days of conservative therapy, after which a solid diet can be resumed. Upon continued improvement, patients can be discharged and can continue their oral antimicrobial course at home for a total of 7–10 days. One study²⁰⁹ found that patients failing to improve at 48 hours of treatment required prolonged hospitalization or surgery. When conservative medical treatment fails, a diligent search for complications is warranted and alternative diagnoses as well as surgical consultation need to be considered (Figure 6).

Complicated diverticulitis—Abscess is the most common complication of diverticulitis (in ~10% of patients. Patients with small abscesses (<3–4 cm in diameter), phlegmons (localized area of inflammation or swelling of the soft tissues) or small amounts of extraluminal air can usually be managed with antimicrobial drugs alone²¹⁰ (Figure 7). Larger abscesses are generally treated with percutaneous drainage when antimicrobial therapy is insufficient. Percutaneous drainage can transform emergency surgery into an elective operation, reducing the need for a two-stage procedure^{181,182}. In carefully selected patients (those who are immunocompromised or those with severe cardiac or pulmonary disease), observation (with no surgery) after percutaneous drainage of colonic diverticular abscess might be attempted^{211,212}. However, current evidence suggests that complicated diverticulitis with abscess associated with a high probability of requiring resective surgery and conservative management alone can frequently result in chronic or recurrent diverticular symptoms^{211,213}.

The surgical approach to complicated diverticulitis is evolving and is generally becoming less aggressive²¹⁴. Surgical resection is usually necessary to relieve symptoms when diverticulitis is complicated by a fistula or chronic obstruction due to stricture. Urgent surgical intervention is required for patients with sepsis and diffuse peritonitis (Hinchey stages III and IV (Figure 5) or for those who do not respond to conservative

therapy^{22,23,181,182}. Historically, sigmoid colectomy with end colostomy (Hartmann procedure, which brings one end of the large intestine out through the intestinal wall) was performed, but this approach is associated with the need for subsequent major surgery to restore bowel continuity. This procedure also brings about a significant rate of perioperative complications and a risk of permanent stomas, albeit related to the patient's disease and comorbidity rather than the surgical procedure itself. Alternatively, sigmoid colectomy with primary anastomosis (with or without diverting loop ileostomy), that appears to be associated with a lower overall mortality, has been proposed²¹⁵. Some European studies²¹⁵ have compared the Hartmann procedure to primary anastomosis and found comparable results. However, the difficulty of applying RCT principles to studies in acute surgical settings and the intrinsic limitations of the studies do not allow definite conclusions²².

Laparoscopic lavage has also been proposed as a means to control purulent (not faeculent) peritonitis, allowing for a subsequent elective resection with primary anastomosis, reducing the risk of permanent stoma^{216,217}. However, at present, its use is not recommended outside clinical trials²². Indeed, a systematic review²¹⁸ concluded that laparoscopic lavage has an increased risk of major complications²¹⁹ compared with primary resection for Hinchey stage III diverticulitis. Primary resection with anastomosis remains the optimal management approach for complicated diverticulitis with perforation, as the rate of stoma reversal and of complications is lower than with the Hartmann procedure²¹⁸. It is evident, however, that the most suitable surgical approach needs to be selected on a case-by-case basis according to individual factors, such as the localization and extent of inflammation as well as patient stability and comorbidity²²⁰ (Figure 7).

Secondary prevention of acute diverticulitis

After an episode of acute diverticulitis, patients might present with recurrent or smoldering diverticulitis, stricture and fistula and often develop chronic gastrointestinal and non-gastrointestinal symptoms²²¹. For example, one study found that, at 1-year follow-up, 40% of patients with CT-confirmed acute diverticulitis complained of mild to moderate abdominal pain and/or changes in bowel habit¹⁹⁶. The overall risk of acute diverticulitis recurrence is ~36% at 5-year follow-up²²². Recurrence usually occurs <12 months of the initial episode and the risk of complications is very low²²³. In a retrospective analysis of patients over an average follow-up period of 6.3 years, patients with acute diverticulitis had a 4.7-fold increased risk of being diagnosed subsequently with IBS²²⁴. The infection-associated gut dysbiosis and the resulting chronic, low-grade mucosal inflammation might underlie this so-called post-diverticulitis IBS (more appropriately termed as “post-diverticulitis SUDD”), which has a pathophysiology similar to that of post-infection IBS²²⁵. Several strategies have been undertaken to prevent recurrence of diverticulitis.

Dietary interventions—The AGA guidelines on management of acute diverticulitis²⁰⁸ *conditionally* recommends a high-fibre diet or fibre supplementation in patients with a history of acute diverticulitis, although, a systematic review²²⁶ found that the evidence for this approach was of very low quality. After resolution of an episode of acute diverticulitis, a high-fibre diet was not effective in preventing recurrence or treating recurring gastrointestinal symptoms compared with a standard or low-fibre diet. Thus, in clinical

practice, dietary restrictions could be substituted with less strict diets. A lack of evidence for the efficacy of probiotics precludes recommending their use for secondary prevention of diverticulitis^{177,208}.

Pharmacological therapies—A meta-analysis of six trials, which evaluated the efficacy of mesalazine in the prevention of recurrent diverticulitis in 2,461 patients, showed no significant difference in the rate of recurrent diverticulitis with mesalazine treatment²²⁷. However, mesalazine use after an episode of diverticulitis should not be precluded. Indeed, in the DIVA trial, mesalazine treatment resulted in fewer and less severe symptoms than placebo, a benefit that persisted at the 9-month follow-up²²⁸. In addition, a small retrospective study of patients with acute uncomplicated diverticulitis found that mesalazine led to faster recovery²²⁹.

In a proof-of-concept study²³⁰, the combination of cyclic rifaximin treatment and fibre supplements reduced the risk of diverticulitis recurrence in patients in remission (HR 2.64, 95% CI 1.08–6.46), a trend later confirmed in an observational study²³¹. Due to the intrinsic limitations of both studies, the current evidence favoring rifaximin use is low. An international, multicenter RCT²³² with a new rifaximin formulation (extended intestinal release) for secondary prevention of acute diverticulitis is ongoing and results are eagerly awaited. Furthermore, a combination of mesalazine and rifaximin (both administered 7 days per month for 12 months) seems to be more effective than rifaximin alone for resolution of symptoms and prevention of diverticulitis (recurrence rate 2.7% versus 13.0%, respectively, at the end of follow-up)²³³. Furthermore, the normalization of the inflammatory indices was faster with the combined treatment²³³. Although rifaximin use can be considered promising, the AGA guidelines do not consider the available evidence to be sufficient to recommend its use for the secondary prevention of diverticulitis²⁰⁸.

A 2012 systematic review concluded that the evidence on medical therapy to prevent recurrent diverticulitis is poor²³⁴. Thus, no recommendation of any non-operative relapse prevention therapy for diverticular disease could be made at that time. Unfortunately, little progress has been made since then. Indeed, no disease-modifying pharmacological treatment for the prevention of acute diverticulitis and/or for treating patients with symptomatic diverticular disease is currently approved in North America or Europe.

Surgery—Surgery is also considered on an elective basis for patients with recurrent, uncomplicated diverticulitis. In the past, surgery was recommended after 2 occurrences and potentially sooner in younger (<50 years of age) patients²³⁵. However, accumulating data on the natural history of the disease have led to the abandonment of this recommendation as most complications (except fistulas and obstruction) occur during the first or second episode and emergency surgery is rarely needed in recurrent disease²². As a consequence, several reviews^{236–238} concluded that there is no evidence to support the practice of elective surgery after two attacks of diverticulitis.

Morbidity is common after elective resection (10–15%) and surgery does not eliminate risk of diverticulitis recurrence²³⁹. Recurrence rate in patients with persistent diverticulitis is likely to be higher. In the DIRECT trial¹⁸⁵, 11% of surgically-treated patients had

anastomotic leakage and 15% of surgically-treated patients required reintervention at 5-year follow-up. However, conservative management (pharmacological treatment combined with dietary and lifestyle changes) resulted in more re-admissions because of recurrence than surgery¹⁸⁵. Both short-term and long-term outcomes of the DIRECT Trial^{185,240} showed that elective sigmoidectomy, despite its inherent risk of complications, results in better quality of life than conservative management in patients with recurrent and persistent abdominal complaints after an episode of diverticulitis. Taking these findings into account, elective surgery is recommended for recurrent, uncomplicated diverticulitis on a case-by-case basis, taking into consideration factors such as severity and frequency of symptoms, effect of surgery on the quality of life, need for immunosuppression, surgical risk profile and patient preference²².

Notably, in the setting of acute diverticulitis (excluding patients with generalized peritonitis, which does represent a surgical emergency), medical and surgical treatments have not been directly compared in RCTs. In the absence of clear evidence in favor of surgery (which is invasive and not devoid of morbidity and mortality²⁴¹), it is reasonable to favor (whenever possible) conservative medical therapy in most patients^{239,242}.

Quality of life

Health-related quality of life (HRQOL) is specified as an individual's or a group's perceived physical and mental health over time²⁴³. By definition, HRQOL refers to the chronic effects of a disease rather than effects during an acute phase. Although patients with diverticular disease face a prolonged disease course and recurrent symptoms owing to prolonged subclinical inflammation^{1,40}, studies assessing the effect of diverticular disease on the quality of life are surprisingly rare. During the disease course, a substantial proportion of patients with diverticular disease have recurrent abdominal pain, change in bowel habits and bloating but without overt symptoms of acute diverticulitis^{121,122}. In addition, both during and after acute diverticulitis recurrences, patients with SUDD attributed a wide range of negative psychological, social, and physical symptoms to their condition, which impaired their quality of life²²¹.

In a 2003 study²⁴⁴ involving 50 patients with SUDD and 50 healthy individuals, personal interview and the IBD quality of life questionnaire²⁴⁴ were used to evaluate HRQoL. The IBD questionnaire addressed four aspects of the patients' quality of life— emotional function, social function, systemic symptoms and gastrointestinal symptoms. Although detailed clinical data describing disease severity were lacking, patients with SUDD had significantly lower scores ($P<0.003$) in all aspects, with lowest scores for systemic and gastrointestinal symptoms than healthy individuals demonstrating that diverticular disease negatively affected patients' quality of life. An Italian study involving 58 patients with SUDD¹⁴⁰ employed the 36-question short form (SF-36) questionnaire²⁴⁵, a general HRQoL questionnaire that measures eight different aspects of a patient's health status and well-being (four domains each for physical health and for mental health), to evaluate the efficacy of pharmacological treatment in improving patients' quality of life. Baseline scores in all eight quality of life domains were lower in patients with SUDD than in general Italian population

and 6 months of treatment with rifaximin or mesalazine improved all quality of life measures.

The diverticulitis quality of life (DV-QOL), a disease targeted questionnaire²²¹ developed based on a cross-sectional validation study involving 197 patients with SUDD, contains 17 items addressing four major disease-specific aspects— physical symptoms, concerns, emotions and behavioural changes. The study concluded that the range of symptoms in patients with SUDD adversely affected their physical, psychological and social well-being, which can be effectively monitored using the DV-QOL.

A long-term extension of the DIABOLO trial²⁴⁶ assessed the effect of persistent symptoms on HRQOL using the visual analog scale (VAS) score from the EuroQol 5D (EQ5D) survey, a general HRQOL questionnaire²⁴⁷, the SF-36 survey²⁴⁵ and the Gastrointestinal Quality of Life Index (GIQLI), a HRQoL questionnaire for gastrointestinal diseases that contains 36 items assessing the four major aspects of a patient's life—physical, social and emotional function, and gastrointestinal symptoms²⁴⁷. At 2-year follow-up, 32–38% of patients reported that persistent symptoms negatively affected the quality of life²⁴⁶. The quality of life was not different between patients treated with antibiotics for acute diverticulitis and the observation group.

Finally, two studies, one in the UK and one in Germany, revealed higher rates of anxiety and depression in patients with diverticular disease than in healthy individuals^{248,249}.

Outlook

Optimal management of diverticular disease requires defined prognostic factors, which can be clinical, laboratory or instrumental measurements (Figure 8). Knowledge on prognostic factors will be crucial in predicting the main complication of the disease, namely acute diverticulitis. Although there are no clear clinical features that are predictive of this progression, patients with SUDD, who have extensive diverticulosis (both in terms of the number of diverticula per segment and the number of colonic segments that contain diverticula), are at higher risk of developing acute diverticulitis^{175,224}. Prognostic factors for recurrence of acute diverticulitis are also important. When acute diverticulitis occurs, some clinical and radiological factors such as family history of diverticulitis (HR 2.2, 95% CI 1.4–3.2), >5 cm length of inflamed colon (HR 1.7, 95% CI 1.3–2.3) and presence of retroperitoneal abscess (HR 4.5, 95% CI 1.1–18.4)²²² might be easily identified as risk factors for recurrence. Other predictive factors identified, include persistent increased faecal calprotectin levels after an episode of acute diverticulitis⁴⁰, although additional studies are needed to identify the ideal cut-off for faecal calprotectin for detecting active inflammation in these patients. In addition, persistent endoscopic and histological inflammation following acute diverticulitis⁴⁴ are well established prognostic factors for recurrence of acute diverticulitis.

Taking all these risk factors into account, it is evident that endoscopic features have an important role in predicting both the occurrence and recurrence of acute diverticulitis. The DICA classification (Figure 4), based on colonoscopy became available only in 2015, which

is surprising, given the high frequency of incidental detection of diverticulosis during routine colonoscopy. The DICA classification could be an important tool for providing a personalized approach in patients with diverticular disease, in particular in preventing acute diverticulitis occurrence and/or recurrence¹²⁹. The first retrospective study evaluating this tool found that treatment was not able to influence the outcomes in patients with either DICA1 or DICA3 in terms of acute diverticulitis occurrence and/or recurrence: this means that patients classified DICA1 are at lower risk of acute diverticulitis and patients classified DICA3 are at higher risk of acute diverticulitis despite a scheduled treatment during the follow-up. Conversely, only patients classified as DICA2 benefitted from a scheduled treatment during the follow-up, being at lower risk of acute diverticulitis occurrence or recurrence compared with those not receiving any treatment during follow-up¹³¹. As medical treatments did not show significant advantage in preventing acute diverticulitis occurrence or recurrence, or preventing need for surgical intervention in patients classified as DICA1 and DICA3, targeting medical treatments only to those classified under DICA2 may save considerable economic resources that could be directed to other health purposes. In this regard, a study estimated that, in Italy, adopting such DICA-driven approach to manage diverticular disease would save >475 million euros per year²⁵⁰.

Another area requiring additional investigation is the correct diagnosis of patients with SUDD. Although in some studies patients with diverticulosis and IBS-like abdominal symptoms continue to be categorized as having ‘symptomatic diverticular disease’^{41,42}, SUDD is a distinct disease entity with clearly defined clinical characteristics, mainly specific characteristics of the abdominal pain²⁵¹. Consequently, patients with diverticulosis who have symptoms resembling those having IBS should be diagnosed as having ‘IBS-like diverticulosis’²⁵². Although other characteristics of patients with SUDD such as increased faecal calprotectin, presence of low-grade mucosal inflammation and increased levels of some pro-inflammatory cytokines²⁵² enable an accurate differential diagnosis, additional studies are needed to establish clear clinical features that are easily identifiable in clinical practice.

Factors that promote progression of diverticulosis to SUDD need to be further elucidated. Although some pathophysiological mechanisms that trigger the occurrence of symptoms (such as environmental factors, colonic dysmotility and visceral hypersensitivity) have been well-studied, understanding of the role of gut microbial dysbiosis is fairly new and is of pivotal importance. However, as discussed earlier, the findings of preliminary studies have not always been consistent. For example, one study reported lower levels of *A. muciniphila* in patients with SUDD than in healthy individuals⁵⁵, whereas another study reported the opposite⁵⁷. Interestingly, an increased abundance of *A. muciniphila* was observed in older individuals compared with younger individuals²⁵³, an observation which overlaps with the general population. Furthermore, a pilot study found that treatment resulted in a lower abundance of *A. muciniphila*, which was restored to pre-treatment levels within 60 days after stopping treatment²⁵⁴. These changes in *A. muciniphila* abundance correlate with abdominal pain in the left lower quadrant and with the faecal metabolome²⁵⁴.

Current studies concerning both faecal and mucosa-associated microbiota in diverticular disease do not allow drawing definite conclusions on the precise alterations (if any) of

intestinal microecology associated with the disease. Many studies present drawbacks and limitations including reduced sample size, not having well-defined inclusion criteria, different patient populations and the methodology adopted. Results across different studies are not always consistent and sometimes actually conflicting^{139,255}. Asymptomatic diverticulosis does not seem to be associated with substantial changes of gut microbiota. However, considerable changes occur in the microbiota composition when diverticulosis evolves into SUDD or acute diverticulitis (in particular, depletion of microbial taxa with purported anti-inflammatory activity). These findings are consistent with the idea that microbiota could be involved in the progression of diverticulosis to SUDD and diverticulitis, but not in the pathogenesis of diverticula. Microbiota-directed therapies might, therefore, represent a rational approach to diverticular disease^{139,255}.

Characterization of the faecal and urinary metabolome is a research area that is likely to improve diagnostic accuracy. The changes in the urinary and faecal metabolome in patients with SUDD involved the hippurate and kynurenine pathways, and six urinary biomarkers provided diagnostic value to distinguish patients with SUDD from healthy individuals⁵⁵. The fecal metabolome in patients with SUDD is characterized by low levels of valerate, butyrate, and choline and by high levels of N-acetyl derivatives, whereas hippurate, methanol and 3,5-dihydroxybenzoate provided discriminatory value for distinguishing between patients with SUDD and healthy individuals²⁵⁶. Metabolomic signatures will likely represent a key aspect for the future characterization of different phenotypes of diverticular disease.

Acknowledgements

The authors thank Prof. Richard H. Hunt (McMaster University) for critical reading of the manuscript, useful discussions and suggestions and Dr Gian Andrea Binda (Biomedical Institute, Genoa) for useful discussion and reviewing the section devoted to surgical management.

References

1. Tursi A Diverticulosis today: unfashionable and still under-researched. *Therapeutic Advances in Gastroenterology* 9, 213–228 (2015).
2. Schieffer KM, Kline BP, Yochum GS & Koltun WA Pathophysiology of diverticular disease. *Expert Review of Gastroenterology & Hepatology* 12, 683–692 (2018). [PubMed: 29846097]
3. Tursi A, Papa A & Danese S Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. *Alimentary Pharmacology & Therapeutics* 42, 664–684 (2015). [PubMed: 26202723]
4. Cuomo R, Cargioli M, Cassarano S, Carabotti M & Annibale B Treatment of diverticular disease, targeting symptoms or underlying mechanisms. *Current Opinion in Pharmacology* 43, 124–131 (2018). [PubMed: 30291995]
5. Sato H et al. Esophageal diverticulum: New perspectives in the era of minimally invasive endoscopic treatment. *World J. Gastroenterol.* 25, 1457–1464 (2019). [PubMed: 30948909]
6. Shah J, Patel K, Sunkara T, Papafragkakis C & Shahidullah A Gastric Diverticulum: A Comprehensive Review. *Inflamm Intest Dis* 3, 161–166 (2019). [PubMed: 31111031]
7. Rangan V & Lamont JT Small Bowel Diverticulosis: Pathogenesis, Clinical Management, and New Concepts. *Curr Gastroenterol Rep* 22, 4 (2020). [PubMed: 31940112]
8. Lanas A, Abad-Baroja D & Lanas-Gimeno A Progress and challenges in the management of diverticular disease: which treatment? *Therapeutic Advances in Gastroenterology* 11, 175628481878905 (2018).

9. Everhart JE & Ruhl CE Burden of Digestive Diseases in the United States Part II: Lower Gastrointestinal Diseases. *Gastroenterology* 136, 741–754 (2009). [PubMed: 19166855]
10. Peery AF et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. *Gastroenterology* 149, 1731–1741.e3 (2015). [PubMed: 26327134]
11. Yamamichi N et al. Trend and Risk Factors of Diverticulosis in Japan: Age, Gender, and Lifestyle/Metabolic-Related Factors May Cooperatively Affect on the Colorectal Diverticula Formation. *PLOS ONE* 10, e0123688 (2015). [PubMed: 25860671] This study assesses the characteristics and the risk factors for diverticulosis in a far east nation.
12. Song JH et al. Clinical Characteristics of Colonic Diverticulosis in Korea: A Prospective Study. *The Korean Journal of Internal Medicine* 25, 140 (2010). [PubMed: 20526386]
13. Golder M et al. Demographic determinants of risk, colon distribution and density scores of diverticular disease. *World J. Gastroenterol.* 17, 1009–1017 (2011). [PubMed: 21448352]
14. Peery AF Colonic Diverticula and Diverticular Disease: 10 Facts Clinicians Should Know. *North Carolina Medical Journal* 77, 220–222 (2016). [PubMed: 27154895]
15. Shahedi K et al. Long-term Risk of Acute Diverticulitis Among Patients With Incidental Diverticulosis Found During Colonoscopy. *Clinical Gastroenterology and Hepatology* 11, 1609–1613 (2013). [PubMed: 23856358] This is a long-term study showing that the risk of acute diverticulitis occurrence in incidental diverticulosis is lower than expected.
16. Faucheron J-L, Roblin X, Bichard P & Heluwaert F The prevalence of right-sided colonic diverticulosis and diverticular haemorrhage. *Colorectal Disease* 15, e266–e270 (2013). [PubMed: 23350931]
17. Peery AF & Sandler RS Diverticular Disease: Reconsidering Conventional Wisdom. *Clinical Gastroenterology and Hepatology* 11, 1532–1537 (2013). [PubMed: 23669306]
18. Gralnek IM, Neeman Z & Strate LL Acute Lower Gastrointestinal Bleeding. *New England Journal of Medicine* 376, 1054–1063 (2017). [PubMed: 28296600]
19. Delvaux M Diverticular disease of the colon in Europe: epidemiology, impact on citizen health and prevention. *Alimentary Pharmacology and Therapeutics* 18, 71–74 (2003). [PubMed: 14531745]
20. JEYARAJAH S et al. Diverticular disease hospital admissions are increasing, with poor outcomes in the elderly and emergency admissions. *Alimentary Pharmacology & Therapeutics* 30, 1171–1182 (2009). [PubMed: 19681811]
21. Binda GA et al. Trends in hospital admission for acute diverticulitis in Italy from 2008 to 2015. *Techniques in Coloproctology* 22, 597–604 (2018). [PubMed: 30196450]
22. Strate LL & Morris AM Epidemiology, Pathophysiology, and Treatment of Diverticulitis. *Gastroenterology* 156, 1282–1298.e1 (2019). [PubMed: 30660732]
23. Böhm SK & Kruis W Lifestyle and other risk factors for diverticulitis. *Minerva Gastroenterol Dietol* 63, 110–118 (2017). [PubMed: 28150481]
24. Jovani M et al. Menopausal Hormone Therapy and Risk of Diverticulitis. *The American Journal of Gastroenterology* 114, 315–321 (2019). [PubMed: 30730324]
25. HJERN F, JOHANSSON C, MELLGREN A, BAXTER NN & HJERN A Diverticular disease and migration - the influence of acculturation to a Western lifestyle on diverticular disease. *Alimentary Pharmacology and Therapeutics* 23, 797–805 (2006). [PubMed: 16556182] This paper is an epidemiological study assessing the role of changing lifestyle on the risk of diverticular disease occurrence.
26. Crowe FL, Appleby PN, Allen NE & Key TJ Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): prospective study of British vegetarians and non-vegetarians. *BMJ* 343, d4131–d4131 (2011). [PubMed: 21771850] This paper is a large study that found fibre was a significant predictive factor for occurrence of diverticular disease.
27. Strate LL, Liu YL, Huang ES, Giovannucci EL & Chan AT Use of Aspirin or Nonsteroidal Anti-inflammatory Drugs Increases Risk for Diverticulitis and Diverticular Bleeding. *Gastroenterology* 140, 1427–1433 (2011). [PubMed: 21320500]
28. Liu P-H et al. Adherence to a Healthy Lifestyle is Associated With a Lower Risk of Diverticulitis among Men. *American Journal of Gastroenterology* 112, 1868–1876 (2017). [PubMed: 29112202]

29. Wess L, Eastwood MA, Edwards CA, Busuttill A & Miller A Collagen alteration in an animal model of colonic diverticulosis. *Gut* 38, 701–706 (1996). [PubMed: 8707115]
30. Wedel T, Barrenschee M, Lange C, Cossais F & Böttner M Morphologic Basis for Developing Diverticular Disease, Diverticulitis, and Diverticular Bleeding. *Visceral Medicine* 31, 76–82 (2015).
31. Cao Y et al. Meat intake and risk of diverticulitis among men. *Gut* 67, 466–472 (2017). [PubMed: 28069830]
32. Ma W et al. Association Between Obesity and Weight Change and Risk of Diverticulitis in Women. *Gastroenterology* 155, 58–66.e4 (2018). [PubMed: 29614301]
33. Strate LL, Liu YL, Alldoori WH, Syngal S & Giovannucci EL Obesity Increases the Risks of Diverticulitis and Diverticular Bleeding. *Gastroenterology* 136, 115–122.e1 (2009). [PubMed: 18996378]
34. Hjern F, Wolk A & Håkansson N Smoking and the risk of diverticular disease in women. *British Journal of Surgery* 98, 997–1002 (2011). [PubMed: 21462366]
35. Strate LL, Liu YL, Alldoori WH & Giovannucci EL Physical Activity Decreases Diverticular Complications. *The American Journal of Gastroenterology* 104, 1221–1230 (2009). [PubMed: 19367267]
36. Ridker PM, Buring JE, Cook NR & Rifai N C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events. *Circulation* 107, 391–397 (2003). [PubMed: 12551861]
37. Pradhan AD C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. *JAMA* 286, 327 (2001). [PubMed: 11466099]
38. Ma W et al. Association Between Inflammatory Diets, Circulating Markers of Inflammation, and Risk of Diverticulitis. *Clinical Gastroenterology and Hepatology* (2019) doi:10.1016/j.cgh.2019.11.011.
39. Humes DJ et al. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. *Neurogastroenterology & Motility* 24, 318–e163 (2012). [PubMed: 22276853]
40. Tursi A et al. Faecal calprotectin in colonic diverticular disease: a case–control study. *International Journal of Colorectal Disease* 24, 49–55 (2008). [PubMed: 18941760]
41. Peery AF et al. Colonic Diverticula Are Not Associated With Mucosal Inflammation or Chronic Gastrointestinal Symptoms. *Clinical Gastroenterology and Hepatology* 16, 884–891.e1 (2018). [PubMed: 28603053]
42. Järbrink-Sehgal ME et al. Diverticulosis, Symptoms and Colonic Inflammation: A Population-Based Colonoscopy Study. *Am. J. Gastroenterol.* 114, 500–510 (2019). [PubMed: 30839393]
43. Lahat A et al. Prolonged Recurrent Abdominal Pain is Associated With Ongoing Underlying Mucosal Inflammation in Patients who had an Episode of Acute Complicated Diverticulitis. *Journal of Clinical Gastroenterology* 53, e178–e185 (2019). [PubMed: 29356787]
44. Tursi A et al. Detection of endoscopic and histological inflammation after an attack of colonic diverticulitis is associated with higher diverticulitis recurrence. *J Gastrointestin Liver Dis* 22, 13–19 (2013). [PubMed: 23539385]
45. Lopez-Garcia E et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. *The American Journal of Clinical Nutrition* 80, 1029–1035 (2004). [PubMed: 15447916]
46. Turnbaugh PJ, Bäckhed F, Fulton L & Gordon JI Diet-Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse Distal Gut Microbiome. *Cell Host & Microbe* 3, 213–223 (2008). [PubMed: 18407065]
47. Turnbaugh PJ & Gordon JI The core gut microbiome, energy balance and obesity. *The Journal of Physiology* 587, 4153–4158 (2009). [PubMed: 19491241]
48. Cotillard A et al. Dietary intervention impact on gut microbial gene richness. *Nature* 500, 585–588 (2013). [PubMed: 23985875]
49. De Filippis F et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. *Gut* 65, 1812–1821 (2015). [PubMed: 26416813]
50. Makki K, Deehan EC, Walter J & Bäckhed F The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease. *Cell Host & Microbe* 23, 705–715 (2018). [PubMed: 29902436]

51. Koh A, De Vadder F, Kovatcheva-Datchary P & Bäckhed F From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell* 165, 1332–1345 (2016). [PubMed: 27259147]
52. Krokowicz L et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study. *International Journal of Colorectal Disease* 29, 387–393 (2013). [PubMed: 24343275]
53. Hullar MA, Sandstrom R, Lampe JW & Strate LL The Fecal Microbiome Differentiates Patients with a History of Diverticulitis vs Those with Uncomplicated Diverticulosis. *Gastroenterology* 152, S624 (2017).
54. Daniels L et al. Fecal microbiome analysis as a diagnostic test for diverticulitis. *European Journal of Clinical Microbiology & Infectious Diseases* 33, 1927–1936 (2014). [PubMed: 24894339] This is the first study to demonstrate that diverticulitis is associated with significant changes in faecal microbiome.
55. Barbara G et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. *Gut* 66, 1252–1261 (2016). [PubMed: 27618836]
56. Kvasnovsky CL et al. Clinical and symptom scores are significantly correlated with fecal microbiota features in patients with symptomatic uncomplicated diverticular disease. *European Journal of Gastroenterology & Hepatology* 30, 107–112 (2018). [PubMed: 29084074] This is the first study that found that changes in microbiota features are linked to symptom's expression in SIDD patients.
57. Tursi A et al. Assessment of Fecal Microbiota and Fecal Metabolome in Symptomatic Uncomplicated Diverticular Disease of the Colon. *Journal of Clinical Gastroenterology* 50, S9–S12 (2016). [PubMed: 27622378]
58. Jones RB et al. An Aberrant Microbiota is not Strongly Associated with Incidental Colonic Diverticulosis. *Scientific Reports* 8, (2018).
59. Painter NS Diverticular disease of the colon—A Disease of Western civilisation. *Disease-a-Month* 16, 1–57 (1970).
60. Maguire LH et al. Genome-wide association analyses identify 39 new susceptibility loci for diverticular disease. *Nature Genetics* 50, 1359–1365 (2018). [PubMed: 30177863]
61. Rosemar A, Ivarsson M-L, Börjesson L & Holmdahl L Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular disease. *Scandinavian Journal of Gastroenterology* 42, 215–220 (2007). [PubMed: 17327941]
62. wedel t. et al. Diverticular disease is associated with an enteric neuropathy as revealed by morphometric analysis. *Neurogastroenterology & Motility* 22, 407–e94 (2010). [PubMed: 20040058]
63. BASSOTTI G et al. Alterations in colonic motility and relationship to pain in colonic diverticulosis. *Clinical Gastroenterology and Hepatology* 3, 248–253 (2005). [PubMed: 15765444]
64. Böttner M et al. The GDNF System Is Altered in Diverticular Disease – Implications for Pathogenesis. *PLoS ONE* 8, e66290 (2013). [PubMed: 23805210]
65. Golder M et al. Smooth muscle cholinergic denervation hypersensitivity in diverticular disease. *The Lancet* 361, 1945–1951 (2003).
66. Bassotti G Interstitial cells of Cajal, enteric nerves, and glial cells in colonic diverticular disease. *Journal of Clinical Pathology* 58, 973–977 (2005). [PubMed: 16126881]
67. Clemens CHM Colorectal visceral perception in diverticular disease. *Gut* 53, 717–722 (2004). [PubMed: 15082591]
68. Barbaro MR et al. Nerve fiber overgrowth in patients with symptomatic diverticular disease. *Neurogastroenterol. Motil.* 31, e13575 (2019). [PubMed: 30838745]
69. Bode MK, Mäk TJKJ Type I and III Collagens in Human Colon Cancer and Diverticulosis. *Scandinavian Journal of Gastroenterology* 35, 747–752 (2000). [PubMed: 10972180]
70. Beighton PH, Murdoch JL & Votteler T Gastrointestinal complications of the Ehlers-Danlos syndrome. *Gut* 10, 1004–1008 (1969). [PubMed: 5308459]
71. Stagi S, Lapi E, Chiarelli F & de Martino M Incidence of diverticular disease and complicated diverticular disease in young patients with Williams syndrome. *Pediatric Surgery International* 26, 943–944 (2010). [PubMed: 20652262]

72. Suster SM Diverticulosis Coli in Association With Marfan's Syndrome. *Archives of Internal Medicine* 144, 203 (1984).
73. Granlund J et al. The genetic influence on diverticular disease - a twin study. *Alimentary Pharmacology & Therapeutics* n/a-n/a (2012) doi:10.1111/j.1365-2036.2012.05069.x.
74. Strate LL et al. Heritability and familial aggregation of diverticular disease: a population-based study of twins and siblings. *Gastroenterology* 144, 736–742.e1; quiz e14 (2013). [PubMed: 23313967]
75. Reichert MC et al. A Variant of COL3A1 (rs3134646) Is Associated With Risk of Developing Diverticulosis in White Men. *Diseases of the Colon & Rectum* 61, 604–611 (2018). [PubMed: 29533249]
76. Connelly TM et al. The TNFSF15 Gene Single Nucleotide Polymorphism rs7848647 Is Associated With Surgical Diverticulitis. *Annals of Surgery* 259, 1132–1137 (2014). [PubMed: 24814505]
77. Beasley WD, Beynon J, Jenkins GJS & Parry JM Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case–control disease association study. *International Journal of Colorectal Disease* 23, 375–381 (2008). [PubMed: 18197409]
78. Coble JL et al. Identification of a rare LAMB4 variant associated with familial diverticulitis through exome sequencing. *Human Molecular Genetics* (2017) doi:10.1093/hmg/ddx204.
79. Camilleri M, Sandler RS & Peery AF Etiopathogenetic Mechanisms in Diverticular Disease of the Colon. *Cellular and Molecular Gastroenterology and Hepatology* 9, 15–32 (2020). [PubMed: 31351939]
80. Sigurdsson S et al. Sequence variants in ARHGAP15, COLQ and FAM155A associate with diverticular disease and diverticulitis. *Nature Communications* 8, (2017).
81. Schafmayer C et al. Genome-wide association analysis of diverticular disease points towards neuromuscular, connective tissue and epithelial pathomechanisms. *Gut* 68, 854–865 (2019). [PubMed: 30661054] This is a large study assessing the role of several genes coding for neuromuscular, connective tissue and epithelial functions in predisposing to the occurrence of diverticular disease.
82. Kruis W, Germer C-T & Leifeld L Diverticular Disease: Guidelines of the German Society for Gastroenterology, Digestive and Metabolic Diseases and the German Society for General and Visceral Surgery. *Digestion* 90, 190–207 (2014). [PubMed: 25413249]
83. Toorenvliet BR, Bakker RFR, Breslau PJ, Merkus JWS & Hamming JF Colonic diverticulitis: a prospective analysis of diagnostic accuracy and clinical decision-making. *Colorectal Disease* 12, 179–186 (2010). [PubMed: 19183330]
84. Farag Soliman M et al. [Primary diagnostics of acute diverticulitis of the sigmoid]. *Ultraschall Med* 25, 342–347 (2004). [PubMed: 15368137]
85. Andeweg CS, Knobben L, Hendriks JCM, Bleichrodt RP & van Goor H How to Diagnose Acute Left-sided Colonic Diverticulitis. *Annals of Surgery* 253, 940–946 (2011). [PubMed: 21346548]
86. Niikura R Colonoscopy can miss diverticula of the left colon identified by barium enema. *World Journal of Gastroenterology* 19, 2362 (2013). [PubMed: 23613630]
87. Andeweg CS et al. Toward an evidence-based step-up approach in diagnosing diverticulitis. *Scandinavian Journal of Gastroenterology* 49, 775–784 (2014). [PubMed: 24874087]
88. Bor R, Fábíán A & Szepes Z Role of ultrasound in colorectal diseases. *World Journal of Gastroenterology* 22, 9477 (2016). [PubMed: 27920469]
89. Lembcke BJ, Strobel D, Dirks K, Becker D & Menzel J Statement of the section internal medicine of the DEGUM - ultrasound obtains pole position for clinical imaging in acute diverticulitis. *Ultraschall Med* 36, 191–195 (2015). [PubMed: 26060863]
90. Swanson SM & Strate LL Acute Colonic Diverticulitis. *Annals of Internal Medicine* 168, ITC65 (2018). [PubMed: 29710265]
91. Min JH et al. The value of initial sonography compared to supplementary CT for diagnosing right-sided colonic diverticulitis. *Japanese Journal of Radiology* 35, 358–365 (2017). [PubMed: 28488205]
92. Schwerk WB, Schwarz S & Rothmund M Sonography in acute colonic diverticulitis. *Diseases of the Colon & Rectum* 35, 1077–1084 (1992). [PubMed: 1425053]

93. Puylaert JBCM Ultrasound of Colon Diverticulitis. *Digestive Diseases* 30, 56–59 (2012). [PubMed: 22572686]
94. Nielsen K et al. The Limited Role of Ultrasound in the Diagnostic Process of Colonic Diverticulitis. *World Journal of Surgery* (2013) doi:10.1007/s00268-013-2423-9.
95. Heverhagen JT, Sitter H, Zielke A & Klose KJ Prospective Evaluation of the Value of Magnetic Resonance Imaging in Suspected Acute Sigmoid Diverticulitis. *Diseases of the Colon & Rectum* 51, 1810–1815 (2008). [PubMed: 18443876]
96. Hollerweger A, Macheiner P, Rettenbacher T, Brunner W & Gritzmann N Colonic diverticulitis: diagnostic value and appearance of inflamed diverticula—sonographic evaluation. *European Radiology* 11, 1956–1963 (2001). [PubMed: 11702128]
97. Liljegren G, Chabok A, Wickbom M, Smedh K & Nilsson K Acute colonic diverticulitis: a systematic review of diagnostic accuracy. *Colorectal Disease* 9, 480–488 (2007). [PubMed: 17573739]
98. Dickerson EC et al. Recurrence of Colonic Diverticulitis: Identifying Predictive CT Findings—Retrospective Cohort Study. *Radiology* 285, 850–858 (2017). [PubMed: 28837412]
99. Ünlü Ç et al. Inter-observer reliability of computed tomographic classifications of diverticulitis. *Colorectal Disease* 16, O212–O219 (2014). [PubMed: 24344689]
100. Ripollés T, Martínez-Pérez MJ, Gómez Valencia DP, Vizúete J & Martín G Sigmoid stenosis caused by diverticulitis vs. carcinoma: usefulness of sonographic features for their differentiation in the emergency setting. *Abdominal Imaging* 40, 2219–2231 (2015). [PubMed: 25962709]
101. Bar-Meir S, Lahat A & Melzer E Role of Endoscopy in Patients with Diverticular Disease. *Digestive Diseases* 30, 60–63 (2012).
102. Lahat A, Yanai H, Sakhnini E, Menachem Y & Bar-Meir S Role of colonoscopy in patients with persistent acute diverticulitis. *World Journal of Gastroenterology* 14, 2763 (2008). [PubMed: 18461662]
103. Mohammed Ilyas MI & Szilagy E Management of Diverticular Bleeding: Evaluation, Stabilization, Intervention, and Recurrence of Bleeding and Indications for Resection after Control of Bleeding. *Clinics in Colon and Rectal Surgery* 31, 243–250 (2018). [PubMed: 29942215]
104. Strate LL & Gralnek IM ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding. *American Journal of Gastroenterology* 111, 459–474 (2016). [PubMed: 26925883]
105. Jensen DM, Machicado GA, Jutabha R & Kovacs TOG Urgent Colonoscopy for the Diagnosis and Treatment of Severe Diverticular Hemorrhage. *New England Journal of Medicine* 342, 78–82 (2000). [PubMed: 10631275]
106. Navaneethan U, Njei B, Venkatesh PGK & Sanaka MR Timing of colonoscopy and outcomes in patients with lower GI bleeding: a nationwide population-based study. *Gastrointestinal Endoscopy* 79, 297–306.e12 (2014). [PubMed: 24060518]
107. Pasha SF et al. The role of endoscopy in the patient with lower GI bleeding. *Gastrointestinal Endoscopy* 79, 875–885 (2014). [PubMed: 24703084]
108. Nagata N et al. Guidelines for Colonic Diverticular Bleeding and Colonic Diverticulitis: Japan Gastroenterological Association. *Digestion* 99 Suppl 1, 1–26 (2019). [PubMed: 30625484]
109. Parkes BM, Obeid FN, Sorensen VJ, Horst HM & Fath JJ The management of massive lower gastrointestinal bleeding. *Am Surg* 59, 676–678 (1993). [PubMed: 8214970]
110. Meyer J et al. Risk of Colorectal Cancer in Patients With Acute Diverticulitis: A Systematic Review and Meta-analysis of Observational Studies. *Clinical Gastroenterology and Hepatology* 17, 1448–1456.e17 (2019). [PubMed: 30056181]
111. Mounce LTA, Price S, Valderas JM & Hamilton W Comorbid conditions delay diagnosis of colorectal cancer: a cohort study using electronic primary care records. *British Journal of Cancer* 116, 1536–1543 (2017). [PubMed: 28494470]
112. Feingold D et al. Practice Parameters for the Treatment of Sigmoid Diverticulitis. *Diseases of the Colon & Rectum* 57, 284–294 (2014). [PubMed: 24509449]

113. Sharma PV, Eglinton T, Hider P & Frizelle F Systematic Review and Meta-analysis of the Role of Routine Colonic Evaluation After Radiologically Confirmed Acute Diverticulitis. *Annals of Surgery* 259, 263–272 (2014). [PubMed: 24169174]
114. Andrade P, Ribeiro A, Ramalho R, Lopes S & Macedo G Routine Colonoscopy after Acute Uncomplicated Diverticulitis - Challenging a Putative Indication. *Digestive Surgery* 34, 197–202 (2016). [PubMed: 27941344]
115. Rottier SJ et al. Meta-analysis of the role of colonoscopy after an episode of left-sided acute diverticulitis. *Br J Surg* 106, 988–997 (2019). [PubMed: 31260589]
116. Kechagias A et al. Index C-reactive protein predicts increased severity in acute sigmoid diverticulitis. *Therapeutics and Clinical Risk Management Volume 14*, 1847–1853 (2018). [PubMed: 30323607]
117. Tursi A Biomarkers in Diverticular Diseases of the Colon. *Digestive Diseases* 30, 12–18 (2012).
118. Nemaikayala DR & Cash BD Excluding irritable bowel syndrome in the inflammatory bowel disease patient. *Current Opinion in Gastroenterology* 35, 58–62 (2019). [PubMed: 30407259]
119. Waugh N et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. *Health Technology Assessment* 17, (2013).
120. Tursi A A critical appraisal of advances in the diagnosis of diverticular disease. *Expert Review of Gastroenterology & Hepatology* 12, 791–796 (2018). [PubMed: 29888630]
121. Cuomo R et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. *European Journal of Clinical Investigation* n/a-n/a (2013) doi:10.1111/eci.12152.
122. Tursi A, Elisei W, Picchio M, Giorgetti GM & Brandimarte G Moderate to Severe and Prolonged Left Lower-abdominal Pain is the Best Symptom Characterizing Symptomatic Uncomplicated Diverticular Disease of the Colon. *Journal of Clinical Gastroenterology* 49, 218–221 (2015). [PubMed: 24583746] This paper is a clinical study showing how clinical characteristics, together with faecal calprotectin expression, might be useful in differentiating SUDD from IBS.
123. Tan WJ et al. Systematic review and meta-analysis of the use of serum procalcitonin levels to predict intra-abdominal infections after colorectal surgery. *International Journal of Colorectal Disease* 33, 171–180 (2018). [PubMed: 29305753]
124. Sager R, Kutz A, Mueller B & Schuetz P Procalcitonin-guided diagnosis and antibiotic stewardship revisited. *BMC Medicine* 15, (2017).
125. Woodhead M et al. Guidelines for the management of adult lower respiratory tract infections--full version. *Clin. Microbiol. Infect.* 17 Suppl 6, E1–59 (2011).
126. Schuetz P et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections in Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd, 2008). doi:10.1002/14651858.cd007498.
127. Jeger V et al. Correction to: Jeger V, et al. Is there a role for procalcitonin in differentiating uncomplicated and complicated diverticulitis in order to reduce antibiotic therapy? *Swiss Medical Weekly* (2018) doi:10.4414/smw.2018.14673.
128. Serum levels of vitamin D are associated with the severity of the endoscopic appearance of diverticular disease of the colon according to DICA classification. *Journal of Gastrointestinal and Liver Diseases* 25, (2016).
129. Tursi A et al. Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. *Dig Dis* 33, 68–76 (2015). [PubMed: 25531499]
130. US National Library of Medicine. *ClinicalTrials.gov*, <https://clinicaltrials.gov/ct2/show/NCT02758860> (2018).
131. Tursi A et al. Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. *United European Gastroenterol J* 4, 604–613 (2016).
132. Tursi A et al. P.02.12 PREDICTIVE VALUE OF THE “DICA” ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF DIVERTICULAR DISEASE OF THE COLON: A 1-YEAR ANALYSIS FROM THE INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY. *Digestive and Liver Disease* 51, e152–e153 (2019). This paper is the first endoscopic

classification for diverticulosis and diverticular disease that have also a predictive value on the outcome of the disease.

133. Unlü C et al. Inter-observer reliability of computed tomographic classifications of diverticulitis. *Colorectal Dis* 16, O212–219 (2014). [PubMed: 24344689]
134. Laméris W et al. Graded compression ultrasonography and computed tomography in acute colonic diverticulitis: Meta-analysis of test accuracy. *European Radiology* 18, 2498–2511 (2008). [PubMed: 18523784]
135. Hinchey EJ, Schaal PG & Richards GK Treatment of perforated diverticular disease of the colon. *Adv Surg* 12, 85–109 (1978). [PubMed: 735943]
136. Wasvary H, Turfah F, Kadro O & Beauregard W Same hospitalization resection for acute diverticulitis. *Am Surg* 65, 632–635; discussion 636 (1999). [PubMed: 10399971]
137. Painter NS & Burkitt DP Diverticular disease of the colon: a deficiency disease of Western civilization. *BMJ* 2, 450–454 (1971). [PubMed: 4930390]
138. Strate LL, Modi R, Cohen E & Spiegel BMR Diverticular Disease as a Chronic Illness: Evolving Epidemiologic and Clinical Insights. *American Journal of Gastroenterology* 107, 1486–1493 (2012). [PubMed: 22777341]
139. Scarpignato C, Barbara G, Lanas A & Strate LL Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. *Therapeutic Advances in Gastroenterology* 11, 175628481877130 (2018).
140. Comparato G et al. Quality of Life in Uncomplicated Symptomatic Diverticular Disease: Is It Another Good Reason for Treatment? *Digestive Diseases* 25, 252–259 (2007). [PubMed: 17827951]
141. Carabotti M, Annibale B, Severi C & Lahner E Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review. *Nutrients* 9, 161 (2017).
142. Papi C, Ciaco A, Koch M & Capurso L Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. *Aliment. Pharmacol. Ther.* 9, 33–39 (1995). This paper is a controlled double-blind study showing the efficacy and safety of cyclic treatment with rifaximin versus placebo in controlling symptoms in SUDD.
143. Schieffer KM et al. The Microbial Ecosystem Distinguishes Chronically Diseased Tissue from Adjacent Tissue in the Sigmoid Colon of Chronic, Recurrent Diverticulitis Patients. *Scientific Reports* 7, (2017).
144. Corazza GR, Di Stefano M & Scarpignato C Treatment of functional bowel disorders: is there room for antibiotics? *Digestion* 73 Suppl 1, 38–46 (2006). [PubMed: 16498251]
145. Kurpad AV & Shetty PS Effects of antimicrobial therapy on faecal bulking. *Gut* 27, 55–58 (1986). [PubMed: 3005139]
146. Frieri G, Pimpo MT & Scarpignato C Management of colonic diverticular disease. *Digestion* 73 Suppl 1, 58–66 (2006). [PubMed: 16498253]
147. Latella G & Scarpignato C Rifaximin in the management of colonic diverticular disease. *Expert Review of Gastroenterology & Hepatology* 3, 585–598 (2009). [PubMed: 19929580]
148. Kasturi KS, Mummadi RR & Jaganmohan S M1695 Cyclical Rifaximin for Symptomatic, Uncomplicated Diverticular Disease: A Meta-Analysis. *Gastroenterology* 134, A-399 (2008).
149. Bianchi M et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. *Alimentary Pharmacology & Therapeutics* 33, 902–910 (2011). [PubMed: 21366632]
150. Scarpignato C & Pelosini I Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential. *Chemotherapy* 51, 36–66 (2005). [PubMed: 15855748]
151. Ponziani FR, Zocco MA, D'Aversa F, Pompili M & Gasbarrini A Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. *World Journal of Gastroenterology* 23, 4491 (2017). [PubMed: 28740337]
152. Gatta L & Scarpignato C Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. *Alimentary Pharmacology & Therapeutics* 45, 604–616 (2017). [PubMed: 28078798]

153. Scarpignato C & Gatta L Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth. *Alimentary Pharmacology & Therapeutics* 38, 1409–1410 (2013). [PubMed: 24206376]
154. Moniuszko A & Rydzewska G The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: a “real-life” study. *Gastroenterology Review* 2, 145–151 (2017).
155. Stallinger S, Eller N & Högenauer C Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease. *Wiener klinische Wochenschrift* 126, 9–14 (2013). [PubMed: 24240607]
156. Copaci I, Constantinescu G, Mihail M, Micu L, Franculescu-Berteau A. Efficacy of Rifaximin vs Dietary Fiber on the Evolution of Uncomplicated Colonic Diverticular Disease. *Surg Gastroenterol Oncol* 2019; 24: 233–240 - DOI: 10.21614/sgo-24-5-233.
157. Di Mario F et al. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. *Journal of Investigative Medicine* 67, 767–770 (2018). [PubMed: 30593541]
158. Lauritano EC et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. *Am. J. Gastroenterol.* 103, 2031–2035 (2008). [PubMed: 18802998]
159. Charúa-Guindic L et al. [Gastroenterology diagnosis and treatment guidelines of diverticular disease of the colon. Treatment.]. *Rev Gastroenterol Mex* 73, 261–264 (2008). [PubMed: 19666286]
160. Andersen JC et al. Danish national guidelines for treatment of diverticular disease. *Dan Med J* 59, C4453 (2012). [PubMed: 22549495]
161. Cuomo R et al. Italian consensus conference for colonic diverticulosis and diverticular disease. *United European Gastroenterology Journal* 2, 413–442 (2014). [PubMed: 25360320]
162. Binda GA et al. Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines. *Techniques in Coloproctology* 19, 615–626 (2015). [PubMed: 26377584]
163. Pietrzak A et al. Polish interdisciplinary consensus on diagnostics and treatment of colonic diverticulosis (2015). *Polish Journal of Surgery* 87, (2015).
164. Diagnosis and treatment of colonic diverticular disease: position paper of the Romanian Society of Gastroenterology and Hepatology. *Journal of Gastrointestinal and Liver Diseases* 27, (2018).
165. Cuomo R, Barbara G & Annibale B Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). *Digestive and Liver Disease* 49, 595–603 (2017). [PubMed: 28215517]
166. Viscomi GC et al., Crystal forms of rifaximin and their effect on pharmaceutical properties. *CrystEngComm* 10: 1074–81 10.1039/B717887E (2008).
167. Blandizzi C, Viscomi GC, Marzo A & Scarpignato C Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. *Pharmacol. Res.* 85, 39–44 (2014). [PubMed: 24836868]
168. Dadgostar P Antimicrobial Resistance: Implications and Costs. *Infect Drug Resist* 12, 3903–3910 (2019). [PubMed: 31908502]
169. Cole KA, Rivard KR & Dumkow LE Antimicrobial Stewardship Interventions to Combat Antibiotic Resistance: an Update on Targeted Strategies. *Curr Infect Dis Rep* 21, 33 (2019). [PubMed: 31473861]
170. Zuccaro V et al. Antibiotic stewardship and empirical antibiotic treatment: How can they get along? *Dig Liver Dis* 49, 579–584 (2017). [PubMed: 28215515]
171. Ponziani FR et al. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. *Expert Opin Drug Saf* 15, 983–991 (2016). [PubMed: 27149541]
172. Pimentel M et al. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. *Dig. Dis. Sci.* 62, 2455–2463 (2017). [PubMed: 28589238]
173. Barbara G, Cremon C, Barbaro MR, Bellacosa L & Stanghellini V Treatment of Diverticular Disease With Aminosalicylates. *Journal of Clinical Gastroenterology* 50, S60–S63 (2016). [PubMed: 27622369]

174. Kruis W et al. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon - a placebo-controlled study. *Alimentary Pharmacology & Therapeutics* 37, 680–690 (2013). [PubMed: 23414061]
175. Tursi A et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. *Aliment. Pharmacol. Ther.* 38, 741–751 (2013). [PubMed: 23957734] This study is a controlled double-blind study showing the efficacy and safety of cyclic treatment with mesalazine, with or without probiotics, versus placebo in controlling symptoms in SUDD and in preventing acute diverticulitis occurrence in patients with SUDD.
176. Picchio M et al. Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis. *Journal of Clinical Gastroenterology* 50, S64–S69 (2016). [PubMed: 27622370]
177. Scarpignato C, Bertelé A & Tursi A Probiotics for the Treatment of Symptomatic Uncomplicated Diverticular Disease. *Journal of Clinical Gastroenterology* 50, S70–S73 (2016). [PubMed: 27622371]
178. Lahner E et al. Probiotics in the Treatment of Diverticular Disease. A Systematic Review. *J Gastrointestin Liver Dis* 25, 79–86 (2016). [PubMed: 27014757]
179. Salem TA, Molloy RG & O'Dwyer PJ Prospective, Five-Year Follow-up Study of Patients with Symptomatic Uncomplicated Diverticular Disease. *Diseases of the Colon & Rectum* 50, 1460–1464 (2007). [PubMed: 17431721]
180. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials. *Journal of Gastrointestinal and Liver Diseases* 27, (2018).
181. Jacobs DO Diverticulitis. *New England Journal of Medicine* 357, 2057–2066 (2007). [PubMed: 18003962]
182. Young-Fadok TM Diverticulitis. *New England Journal of Medicine* 379, 1635–1642 (2018). [PubMed: 30354951]
183. Slim K, Joris J & Beyer-Berjot L The end of antibiotics in the management of uncomplicated acute diverticulitis. *Journal of Visceral Surgery* 156, 373–375 (2019). [PubMed: 31699337]
184. Rottier SJ et al. Complicated Disease Course in Initially Computed Tomography-Proven Uncomplicated Acute Diverticulitis. *Surgical Infections* 20, 453–459 (2019). [PubMed: 30932745]
185. Bolkenstein HE et al. Long-term Outcome of Surgery Versus Conservative Management for Recurrent and Ongoing Complaints After an Episode of Diverticulitis: 5-year Follow-up Results of a Multicenter Randomized Controlled Trial (DIRECT-Trial). *Ann. Surg.* 269, 612–620 (2019). [PubMed: 30247329]
186. Jaung R et al. Uncomplicated Acute Diverticulitis: Identifying Risk Factors for Severe Outcomes. *World Journal of Surgery* 41, 2258–2265 (2017). [PubMed: 28401253]
187. Sánchez-Velázquez P, Grande L & Pera M Outpatient treatment of uncomplicated diverticulitis. *European Journal of Gastroenterology & Hepatology* 28, 622–627 (2016). [PubMed: 26891198]
188. Balasubramanian I et al. Out-Patient Management of Mild or Uncomplicated Diverticulitis: A Systematic Review. *Digestive Surgery* 34, 151–160 (2016). [PubMed: 27701164]
189. van Dijk ST et al. A systematic review and meta-analysis of outpatient treatment for acute diverticulitis. *International Journal of Colorectal Disease* 33, 505–512 (2018). [PubMed: 29532202]
190. Cirocchi R et al. Is the outpatient management of acute diverticulitis safe and effective? A systematic review and meta-analysis. *Techniques in Coloproctology* 23, 87–100 (2019). [PubMed: 30684110]
191. Shabanzadeh DM & Wille-Jørgensen P Antibiotics for uncomplicated diverticulitis. *Cochrane Database of Systematic Reviews* (2012) doi:10.1002/14651858.cd009092.pub2.
192. Schug-Pass C, Geers P, Hügel O, Lippert H & Köckerling F Prospective randomized trial comparing short-term antibiotic therapy versus standard therapy for acute uncomplicated sigmoid diverticulitis. *International Journal of Colorectal Disease* 25, 751–759 (2010). [PubMed: 20140619]

193. van de Wall BJM et al. Dietary restrictions for acute diverticulitis: evidence-based or expert opinion? *Int J Colorectal Dis* 28, 1287–1293 (2013). [PubMed: 23604409]
194. Stam M. a. W. et al. An unrestricted diet for uncomplicated diverticulitis is safe: results of a prospective diverticulitis diet study. *Colorectal Dis* 19, 372–377 (2017). [PubMed: 27611011]
195. Rezapour M & Stollman N Antibiotics in Uncomplicated Acute Diverticulitis: To Give or Not to Give? *Inflammatory Intestinal Diseases* 3, 75–79 (2018). [PubMed: 30733951]
196. Chabok A, Pählman L, Hjern F, Haapaniemi S & Smedh K Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. *British Journal of Surgery* 99, 532–539 (2012). [PubMed: 22290281]
197. Daniels L et al. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis. *British Journal of Surgery* 104, 52–61 (2016). [PubMed: 27686365]
198. Emile SH, Elfeki H, Sakr A & Shalaby M Management of acute uncomplicated diverticulitis without antibiotics: a systematic review, meta-analysis, and meta-regression of predictors of treatment failure. *Techniques in Coloproctology* 22, 499–509 (2018). [PubMed: 29980885]
199. Mocanu V et al. The role of antibiotics in acute uncomplicated diverticulitis: A systematic review and meta-analysis. *The American Journal of Surgery* 216, 604–609 (2018). [PubMed: 29454479]
200. Au S & Aly EH Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics: A Systematic Review and Meta-analysis. *Dis. Colon Rectum* 62, 1533–1547 (2019). [PubMed: 30663999]
201. Desai M, Fathallah J, Nutalapati V & Saligram S Antibiotics Versus No Antibiotics for Acute Uncomplicated Diverticulitis: A Systematic Review and Meta-analysis. *Dis. Colon Rectum* 62, 1005–1012 (2019). [PubMed: 30664553]
202. Tandon A, Fretwell VL, Nunes QM & Rooney PS Antibiotics vs no antibiotics in the treatment of acute uncomplicated diverticulitis - a systematic review and meta-analysis. *Colorectal Disease* 20, 179–188 (2018).
203. van Dijk ST et al. Predictive factors on CT imaging for progression of uncomplicated into complicated acute diverticulitis. *International Journal of Colorectal Disease* 32, 1693–1698 (2017). [PubMed: 29075917]
204. Daniels L et al. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis. *Br J Surg* 104, 52–61 (2017). [PubMed: 27686365]
205. Au S & Aly EH Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics. *Diseases of the Colon & Rectum* 62, 1533–1547 (2019). [PubMed: 30663999]
206. Sartelli M et al. WSES Guidelines for the management of acute left sided colonic diverticulitis in the emergency setting. *World J Emerg Surg* 11, 37 (2016). [PubMed: 27478494]
207. van Dijk ST et al. Long-Term Effects of Omitting Antibiotics in Uncomplicated Acute Diverticulitis. *Am. J. Gastroenterol.* 113, 1045–1052 (2018). [PubMed: 29700480]
208. Stollman N et al. American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. *Gastroenterology* 149, 1944–1949 (2015). [PubMed: 26453777]
209. Evans J Does a 48-Hour Rule Predict Outcomes in Patients with Acute Sigmoid Diverticulitis? *Journal of Gastrointestinal Surgery* 12, 577–582 (2008). [PubMed: 18175192]
210. Gregersen R, Mortensen LQ, Burcharth J, Pommegaard H-C & Rosenberg J Treatment of patients with acute colonic diverticulitis complicated by abscess formation: A systematic review. *International Journal of Surgery* 35, 201–208 (2016). [PubMed: 27741423]
211. Gaertner WB et al. Percutaneous drainage of colonic diverticular abscess: is colon resection necessary? *Dis. Colon Rectum* 56, 622–626 (2013). [PubMed: 23575402]
212. Jalouta T, Jrebi N, Luchtefeld M & Ogilvie JW Diverticulitis recurrence after percutaneous abscess drainage. *International Journal of Colorectal Disease* 32, 1367–1373 (2017). [PubMed: 28555444]
213. Lamb MN & Kaiser AM Elective Resection Versus Observation After Nonoperative Management of Complicated Diverticulitis With Abscess. *Diseases of the Colon & Rectum* 57, 1430–1440 (2014). [PubMed: 25380010]

214. Biondo S The diminishing role of surgery for acute diverticulitis. *British Journal of Surgery* 106, 308–309 (2019). [PubMed: 30811045]
215. Halim H, Askari A, Nunn R & Hollingshead J Primary resection anastomosis versus Hartmann's procedure in Hinchey III and IV diverticulitis. *World J Emerg Surg* 14, 32 (2019). [PubMed: 31338117]
216. Cirocchi R et al. Laparoscopic lavage versus surgical resection for acute diverticulitis with generalised peritonitis: a systematic review and meta-analysis. *Techniques in Coloproctology* 21, 93–110 (2017). [PubMed: 28197792]
217. Penna M, Markar SR, Mackenzie H, Hompes R & Cunningham C Laparoscopic Lavage Versus Primary Resection for Acute Perforated Diverticulitis. *Annals of Surgery* 267, 252–258 (2018). [PubMed: 28338510]
218. Acuna SA et al. Operative Strategies for Perforated Diverticulitis: A Systematic Review and Meta-analysis. *Dis. Colon Rectum* 61, 1442–1453 (2018). [PubMed: 30371549]
219. Dindo D, Demartines N & Clavien P-A Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann. Surg.* 240, 205–213 (2004). [PubMed: 15273542]
220. Biondo S, Lopez Borao J, Millan M, Kreisler E & Jaurieta E Current status of the treatment of acute colonic diverticulitis: a systematic review. *Colorectal Disease* 14, e1–e11 (2011).
221. Spiegel BMR et al. Development and validation of a disease-targeted quality of life instrument for chronic diverticular disease: the DV-QOL. *Quality of Life Research* 24, 163–179 (2014). [PubMed: 25059533] This is the first study that developed and validated a specific quality of questionnaire for diverticular disease.
222. Hall JF et al. Long-Term Follow-up After an Initial Episode of Diverticulitis: What Are the Predictors of Recurrence? *Diseases of the Colon & Rectum* 54, 283–288 (2011). [PubMed: 21304297]
223. Eglinton T et al. Patterns of recurrence in patients with acute diverticulitis. *British Journal of Surgery* 97, 952–957 (2010). [PubMed: 20474006]
224. Cohen E et al. Increased Risk for Irritable Bowel Syndrome After Acute Diverticulitis. *Clinical Gastroenterology and Hepatology* 11, 1614–1619 (2013). [PubMed: 23524129]
225. Barbara G et al. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. *Gastroenterology* 156, 46–58.e7 (2019). [PubMed: 30009817]
226. Dahl C et al. Evidence for Dietary Fibre Modification in the Recovery and Prevention of Reoccurrence of Acute, Uncomplicated Diverticulitis: A Systematic Literature Review. *Nutrients* 10, 137 (2018).
227. Khan RMA, Ali B, Hajibandeh S & Hajibandeh S Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. *Colorectal Disease* 20, 469–478 (2018). [PubMed: 29520987]
228. Stollman N, Magowan S, Shanahan F, Quigley EMM & DIVA Investigator Group. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. *J. Clin. Gastroenterol.* 47, 621–629 (2013). [PubMed: 23426454]
229. Nespoli L Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis. *World Journal of Gastroenterology* 21, 8366 (2015). [PubMed: 26217088]
230. Lanas A, Ponce J, Bignamini A & Mearin F One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study. *Dig Liver Dis* 45, 104–109 (2013). [PubMed: 23092785]
231. Festa V et al. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. *Eur Rev Med Pharmacol Sci* 21, 1397–1404 (2017). [PubMed: 28387885]
232. US National Library of Medicine. [ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03469050](https://clinicaltrials.gov/ct2/show/NCT03469050) (2019).
233. Tursi A, Brandimarte G & Daffinà R Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. *Digestive and Liver Disease* 34, 510–515 (2002). [PubMed: 12236485]

234. Ünlü Ç, Daniels L, Vrouenraets BC & Boermeester MA Systematic review of medical therapy to prevent recurrent diverticulitis. *International Journal of Colorectal Disease* 27, 1131–1136 (2012). [PubMed: 22576905]
235. Aydin HN & Remzi FH Diverticulitis: when and how to operate? *Digestive and Liver Disease* 36, 435–445 (2004). [PubMed: 15285520]
236. Janes S, Meagher A & Frizelle FA Elective surgery after acute diverticulitis. *British Journal of Surgery* 92, 133–142 (2005). [PubMed: 15685694]
237. Collins D & Winter DC Elective Resection for Diverticular Disease: An Evidence-Based Review. *World Journal of Surgery* 32, 2429–2433 (2008). [PubMed: 18712563]
238. Regenbogen SE, Hardiman KM, Hendren S & Morris AM Surgery for Diverticulitis in the 21st Century. *JAMA Surgery* 149, 292 (2014). [PubMed: 24430164]
239. Strate LL, Peery AF & Neumann I American Gastroenterological Association Institute Technical Review on the Management of Acute Diverticulitis. *Gastroenterology* 149, 1950–1976.e12 (2015). [PubMed: 26453776]
240. van de Wall BJM et al. Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2, 13–22 (2017). [PubMed: 28404008]
241. Haas JM, Singh M & Vakil N Mortality and complications following surgery for diverticulitis: Systematic review and meta-analysis. *United European Gastroenterol J* 4, 706–713 (2016).
242. Peppas G, Bliziotis IA, Oikonomaki D & Falagas ME Outcomes after medical and surgical treatment of diverticulitis: A systematic review of the available evidence. *Journal of Gastroenterology and Hepatology* 22, 1360–1368 (2007). [PubMed: 17716342]
243. Centers for Disease Control and Prevention. Health-Related Quality of Life (HRQOL) [online], <https://www.cdc.gov/hrqol/index.htm> (2018).
244. Bolster LT & Papagrigroriadis S Diverticular disease has an impact on quality of life - results of a preliminary study. *Colorectal Disease* 5, 320–323 (2003). [PubMed: 12814409]
245. McHorney CA, Ware JE, Rachel Lu JF & Sherbourne CD The MOS 36-Item Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient Groups. *Medical Care* 32, 40–66 (1994). [PubMed: 8277801]
246. van Dijk ST et al. Quality of Life and Persistent Symptoms After Uncomplicated Acute Diverticulitis. *Diseases of the Colon & Rectum* 62, 608–614 (2019). [PubMed: 30807455]
247. EuroQol - a new facility for the measurement of health-related quality of life. *Health Policy* 16, 199–208 (1990). [PubMed: 10109801]
248. Eypasch E et al. Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument. *British Journal of Surgery* 82, 216–222 (1995). [PubMed: 7749697]
249. Humes DJ, Simpson J, Neal KR, Scholefield JH & Spiller RC Psychological and colonic factors in painful diverticulosis. *British Journal of Surgery* 95, 195–198 (2007).
250. Tursi A et al. Impact of diverticular inflammation and complication assessment classification on the burden of medical therapies in preventing diverticular disease complications in Italy. *Annals of Translational Medicine* 5, 320–320 (2017). [PubMed: 28861417]
251. Tursi A & Scarpignato C Symptomatic Uncomplicated Diverticular Disease: Chronic Abdominal Pain in Diverticulosis Is Not Enough to Make the Diagnosis. *Clinical Gastroenterology and Hepatology* 16, 2001–2002 (2018). [PubMed: 30454933]
252. Tursi A Diverticular Disease of the Colon and Irritable Bowel Syndrome: It Is Time to Differentiate. *American Journal of Gastroenterology* 110, 774–775 (2015).
253. Biagi E et al. Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians. *PLoS ONE* 5, e10667 (2010). [PubMed: 20498852]
254. Laghi L et al. Impact of treatments on fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon: a pilot study. *J. Biol. Regul. Homeost. Agents* 32, 1421–1432 (2018). [PubMed: 30574746] This paper demonstrated the influence of the current SUDD treatments on faecal microbiota and on urinary and faecal metabolome.
255. Ticinesi A et al. Diverticular Disease: a Gut Microbiota Perspective. *Journal of Gastrointestinal and Liver Diseases* 28, 327–337 (2019). [PubMed: 31517330]

256. Tursi A et al. Urinary metabolic profiling and symptomatic uncomplicated diverticular disease of the colon. *Clinics and Research in Hepatology and Gastroenterology* 41, 344–346 (2017). [PubMed: 28286055]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. Diverticulosis and diverticular disease.

a Diverticulosis can occur in any part of the colon. However, in western countries it generally occurs in the left (descending and sigmoid) colon involving the mucosa and submucosa, whereas in eastern countries protrusion generally occurs in the right colon (ascending) involving all colonic layers. Faecal stasis and faecal impaction in the diverticulum might lead to gut dysbiosis, resulting in the development of symptoms (symptomatic uncomplicated diverticular disease; SUDD) and, sometimes, macroscopic evidence of diverticular inflammation (acute diverticulitis). Diverticular haemorrhage might also occur and is more commonly observed in eastern than in western populations. **b** |SUDD is characterized by absence of macroscopic evidence of inflammation (left panel), but histology often shows patchy lymphoplasmacytic inflammation with lymphoid follicles that expand the lamina propria (arrow; right). Magnification 40×. **c** | Sometimes patients have persisting abdominal pain following acute diverticulitis, a clinical situation called post-diverticulitis SUDD. In these patients, endoscopy may not show signs of inflammation (left panel), and inflammation is generally located at the bottom of colonic crypt by histology (circled, right panel). Magnification 10×. **d** | Diverticular inflammation in acute diverticulitis can be observed at endoscopy (left panel), and acute and chronic inflammatory infiltrate, as well as cryptitis (thick white arrow; right panel) by histology. Magnification 100×. All histological images are haematoxylin and eosin staining of paraffin-fixed samples. Histological images kindly provided by Dr. C. D. Inchingolo (Andria, Italy) and Professor M. Walker (Newcastle, Australia).




Figure 2. Proposed biological mechanisms for diverticular disease.

a | Diverticulosis is hypothesized to be the result of neuromuscular abnormalities such as alterations in collagen and the enteric nervous system, in the setting of increased intraluminal pressure. **b** | Symptomatic uncomplicated diverticular disease (SUDD) can arise from an altered intestinal microbiota leading to chronic, low-grade inflammation mediated by tachykinins. Increased nerve sprouting lead to subsequent visceral hypersensitivity. **c** | Alterations in the intestinal microbiota leading to mucosal barrier dysfunction and inflammation and/or local trauma from a faecalith are proposed mechanisms for

diverticulitis. **d** | Diverticular hemorrhage occurs at sites of asymmetrical vascular thickening. Risk factors for vascular injury such as obesity and hypertension and luminal trauma contribute to bleeding.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. Cross-sectional imaging of diverticulosis and diverticular disease.

Colonic diverticulosis can be clearly visualized using ultrasonography (panel **a**), CT (panel **b**) and MRI (panel **c**). Absence of pericolonic involvement (namely absence of thickening of the diverticular wall and absence of involvement of pericolonic fat) is indicative of a lack of inflammation (Transversal section of sigmoid colon characterised by thickened muscularis propria (mp), with a diverticulum appearing as hyperechoic lesion (arrow) with posterior hypoechoic halo; panel **a**). Ultrasonography can also very useful in detecting acute inflammation of diverticula (Transversal section of sigmoid colon characterised by thickened muscularis propria, with an inflamed diverticulum appearing as hypoechoic protrusion (arrow) surrounded by hyperpoechoic mesenteric tissue; panel **d**). CT can reveal thickening of diverticular wall with inflammation of the pericolonic fat (the so-called fat stranding, white arrow, panel **e**), and MRI can show also diverticular inflammation (thin white arrow, panel **f**). Images in panel **a** and panel **d** are provided by Professor G. Maconi (Milan, Italy); images in panel **b**, **c**, **e** and **f** are provided by Dr. M. Maiorano (Andria, Italy).




Figure 4. The DICA classification system.

The Diverticular Inflammation and Complication Assessment (DICA) classification is the first endoscopic classification developed specifically to describe objectively the presence of diverticulosis in the colon and signs of current or past diverticular inflammation. This classification consists of four main colonic characteristics (the location of diverticulosis, the number of diverticula in each colonic segment, the presence or absence of inflammation, including SCAD, and the presence or absence of complications). Subfeatures are considered and scored. If two different grades of severity are detected at the same time (for example, some diverticula with hyperaemia and others showing erosions), the more severe grade of inflammation (for example, erosions instead of hyperaemia) must be scored and the sum of the scores leads to three different DICA scores: DICA1, DICA 2, and DICA 3.




Figure 5. Clinical presentations of acute diverticulitis.

The clinical presentation of diverticulitis, in which diverticula become inflamed or infected, depends on the location of the affected diverticulum, the severity of the inflammatory process, and the presence of complications. Colonic diverticula have narrow necks that can be easily obstructed by fecal matter. Obstruction of the neck initiates a cascade of events that might lead to distention of the sac, bacterial overgrowth, vascular compromise, and perforation (that is, a hole in the wall of the large bowel). Most perforations are localized and contained, so that uncomplicated diverticulitis is present as small localized pericolic abscess. Complicated diverticulitis usually results from worsening of the infection. If this is the case, large perforations develop with consequent mesenteric abscesses, free perforation and fecal peritonitis. This description, which classifies acute diverticulitis in four stages, was first developed by Hinchey et al¹³⁵. Fistulas and obstruction might suddenly develop during an episode of diverticulitis or can be a late complication. Diverticular haemorrhage, however, represents a non-infective complication.




Figure 6. Algorithm for the management of acute uncomplicated diverticulitis.

The clinical suspicion of acute diverticulitis needs to be confirmed by imaging (US and/or CT scan) and laboratory parameters (leukocyte count, erythrocyte sediment rate and CRP, which correlates with the severity of the disease). In the setting of acute uncomplicated diverticulitis, normal WBC and low PCR (together with absence of fever) characterize patients as low-risk, in whom outpatient treatment is feasible and omission of antimicrobial therapy is safe. Besides comorbidities, immunosuppression and the availability of outpatient support need to be taken into account. Outpatients should be treated with a clear (low-fibre) liquid diet and antimicrobials should only be given in selected cases. For patients needing admission, intravenous fluids and intravenous antimicrobials should be administered. In both low-risk and high-risk patients, improvement of symptoms is expected within 2–3 days and then, normal diet can be resumed. If improvement continues, patients might be discharged to complete a 7–10-day antibiotic course at home, if deemed necessary. Failure of conservative medical treatment warrants a diligent search for complications, consideration of alternative diagnoses and surgical consultation.




Figure 7. Management of acute complicated diverticulitis.

Evaluation and treatment approach of complicated disease depends on the severity of presentation, presence of complications (peritonitis, abscess), and comorbid conditions. Abdominal CT scan is very useful to diagnose diverticular complications according to the Hinchey classification. Patients with small abscesses are usually managed by antimicrobial drugs and liquid diet. If antimicrobial therapy is ineffective, larger abscesses need to be treated by percutaneous drainage, which can allow subsequent elective surgery. In addition to medical treatment, in case of diffuse peritonitis, resection surgery is mandatory. The most suitable surgical approach needs to be selected on a case-by-case basis, according to individual factors such as the extent of the inflammation in the area of the proposed anastomosis and patient stability and comorbidity. Modified from Ref#22

^aRecommended by current guidelines, but some evidence to suggest good outcomes without resection in selected patients




Figure 8. Current and future predictors of outcome in diverticular disease.

Predictors of outcome in diverticular disease have been identified, including family history, imaging characteristics (such as length of the involved colon, or retroperitoneal abscesses) and laboratory parameters (raised fecal calprotectin during the follow up). Future predictors include endoscopic characteristics of the affected colon, according to the Diverticular Inflammation and Complication Assessment (DICA) classification. Other future predictors, which need further studies to confirm the preliminary results, are the identification of changes in the colonic microbiota and in the faecal and urinary metabolomes in patients with diverticular disease. These predictors might hopefully help to identify patients with diverticulosis, who will develop diverticular disease.

Table 1.

Modifiable factors associated with incident diverticulitis.

Risk factor	Category ^a	Relative risk (95% CI) ^b	Recommendation for prevention
Diet			
Fibre	Highest quintile	0.59 (0.46–0.78)	Increase consumption
Nuts	>2 times per week	0.80 (0.63–1.01)	Increase consumption
Popcorn	>2 times per week	0.72 (0.56–0.92)	Increase consumption
Vegetarian diet	Yes or no	0.69 (0.55–0.86)	Implement or adopt
Western dietary pattern	Highest quintile	1.55 (1.20–1.99)	Reduce fat and refined foods
Red meat	Highest quintile	1.58 (1.19–2.11)	Reduce consumption
Lifestyle			
Physical activity	Highest quintile	0.75 (0.58–0.95)	Increase physical activity
BMI	BMI ≥ 30 kg per m ²	1.78 (1.08–2.94)	Reduce BMI
Waist-to-hip ratio	Highest quintile	1.62 (1.23–2.14)	Reduce fat consumption
Smoking	Current or ≥ 15 cigarettes per day	1.56 (1.42–1.72)	Quitting
Medication			
Non-aspirin NSAIDs	≥ 2 times per week	1.72 (1.40–2.11)	Avoid intake
Aspirin	Ever or ≥ 2 times per week	1.25 (1.05–1.47)	Avoid intake
All NSAIDs	≥ 2 times per week	1.65 (1.36–2.01)	Avoid intake
Corticosteroids	Current use	2.74 ^c (1.63–4.61)	Avoid intake
Opiate analgesics	Current use	2.16 ^c (1.55–3.01)	Avoid intake
Postmenopausal hormones	Past use	1.35 (1.25–1.45) ^d	Caution in taking hormonal replacement therapy ^d

Effect estimates are from select large population-based cohort or case–controls studies (modified to from Ref 23).

category when compared with lowest category.

^b Adjusted for potential confounders.

^c represents odds ratio.

^d Data from Ref 24.